
    
<!DOCTYPE html>




<html lang="en" >
<head >
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">

    <!-- Mobile properties -->
    <meta name="HandheldFriendly" content="True">
    <meta name="MobileOptimized" content="320">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">

  
    <!-- Stylesheets -->
    <link rel="stylesheet" href="/pmc/static/CACHE/css/output.cc84172e9e16.css" type="text/css">
  
  <link rel="stylesheet" href="/pmc/static/CACHE/css/output.b634933a977d.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.913c7dcab8ff.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.3766d7ad0d2d.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.e3c3c2c84eb3.css" type="text/css">

  
    <link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/font-awesome/4.7.0/css/font-awesome.min.css"/>
  
<link type="text/css" href="/pmc/static/bundles/base/base.a2ef7ca69e4b20dff539.css" rel="stylesheet" />


    <link rel="stylesheet" href="/corehtml/pmc/css/fonts/stix/stixfonts.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/3.18/pmcrefs1.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/pmc2020_1.1/ncbi_web.min.css?_=a" type="text/css" /><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-journal.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style>

    <link type="text/css" href="/pmc/static/bundles/article/article.3c5d12ff2e4beea20136.css" rel="stylesheet" />
    <link type="text/css" href="/pmc/static/django_pmc_cite_box/lib/cite-box.css" rel="stylesheet" />


    <title>Design of Glycoengineered
IL-4 Antagonists
Employing Chemical and Biosynthetic Glycosylation - PMC</title>

  
  <!-- Favicons -->
  <link rel="shortcut icon" type="image/ico" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.ico" />
  <link rel="icon" type="image/png" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.png" />

  <!-- 192x192, as recommended for Android
  http://updates.html5rocks.com/2014/11/Support-for-theme-color-in-Chrome-39-for-Android
  -->
  <link rel="icon" type="image/png" sizes="192x192" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-192.png" />

  <!-- 57x57 (precomposed) for iPhone 3GS, pre-2011 iPod Touch and older Android devices -->
  <link rel="apple-touch-icon-precomposed" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-57.png">
  <!-- 72x72 (precomposed) for 1st generation iPad, iPad 2 and iPad mini -->
  <link rel="apple-touch-icon-precomposed" sizes="72x72" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-72.png">
  <!-- 114x114 (precomposed) for iPhone 4, 4S, 5 and post-2011 iPod Touch -->
  <link rel="apple-touch-icon-precomposed" sizes="114x114" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-114.png">
  <!-- 144x144 (precomposed) for iPad 3rd and 4th generation -->
  <link rel="apple-touch-icon-precomposed" sizes="144x144" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-144.png">



    
        <!-- Logging params: Pinger defaults -->

<meta name="ncbi_app" content="pmc-frontend" />

<meta name="ncbi_db" content="pmc" />

<meta name="ncbi_phid" content="322C300B24F392050000529DACE0FD4B.1.m_2" />


        <!-- Logging params: Pinger custom -->

<meta name="ncbi_pdid" content="article" />

<meta name="ncbi_op" content="retrieved" />

<meta name="ncbi_app_version" content="0.0" />

<meta name="ncbi_domain" content="acsomega" />

<meta name="ncbi_type" content="fulltext" />

<meta name="ncbi_pcid" content="/articles/PMC10357448/" />


    


    <script>
        
            var ncbiBaseUrl = "https://www.ncbi.nlm.nih.gov";
        
        var useOfficialGovtHeader = true;
    </script>


    <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357448/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="citation_journal_title" content="ACS Omega" /><meta name="citation_title" content="Design of Glycoengineered&#10;IL-4 Antagonists&#10;Employing Chemical and Biosynthetic Glycosylation" /><meta name="citation_author" content="Sarah Thomas" /><meta name="citation_author_institution" content="Department of Molecular Plant Physiology and Biophysics, Julius-von-Sachs Institute of the University Wuerzburg, Julius-von-Sachs Platz 2, D-97082 Wuerzburg, Germany" /><meta name="citation_author" content="Juliane E. Fiebig" /><meta name="citation_author_institution" content="Department of Molecular Plant Physiology and Biophysics, Julius-von-Sachs Institute of the University Wuerzburg, Julius-von-Sachs Platz 2, D-97082 Wuerzburg, Germany" /><meta name="citation_author" content="Eva-Maria Kuhn" /><meta name="citation_author_institution" content="Department of Molecular Plant Physiology and Biophysics, Julius-von-Sachs Institute of the University Wuerzburg, Julius-von-Sachs Platz 2, D-97082 Wuerzburg, Germany" /><meta name="citation_author" content="Dominik S. Mayer" /><meta name="citation_author_institution" content="Department of Molecular Plant Physiology and Biophysics, Julius-von-Sachs Institute of the University Wuerzburg, Julius-von-Sachs Platz 2, D-97082 Wuerzburg, Germany" /><meta name="citation_author" content="Sebastian Filbeck" /><meta name="citation_author_institution" content="Department of Molecular Plant Physiology and Biophysics, Julius-von-Sachs Institute of the University Wuerzburg, Julius-von-Sachs Platz 2, D-97082 Wuerzburg, Germany" /><meta name="citation_author" content="Werner Schmitz" /><meta name="citation_author_institution" content="Department of Biochemistry and Molecular Biology, Biocenter of the University Wuerzburg, Am Hubland, D-97074 Wuerzburg, Germany" /><meta name="citation_author" content="Markus Krischke" /><meta name="citation_author_institution" content="Department of Pharmaceutical Biology, Julius-von-Sachs Institute of the University Wuerzburg, Julius-von-Sachs Platz 2, D-97082 Wuerzburg, Germany" /><meta name="citation_author" content="Roswitha Gropp" /><meta name="citation_author_institution" content="Department of General- Visceral-, Vascular- and Transplantation Surgery, Hospital of the LMU, Nussbaumstr. 20, 80336 Munich, Germany" /><meta name="citation_author" content="Thomas D. Mueller" /><meta name="citation_author_institution" content="Department of Molecular Plant Physiology and Biophysics, Julius-von-Sachs Institute of the University Wuerzburg, Julius-von-Sachs Platz 2, D-97082 Wuerzburg, Germany" /><meta name="citation_publication_date" content="2023/07/07" /><meta name="citation_issue" content="28" /><meta name="citation_volume" content="8" /><meta name="citation_firstpage" content="24841" /><meta name="citation_doi" content="10.1021/acsomega.3c00726" /><meta name="citation_abstract_html_url" content="/pmc/articles/PMC10357448/?report=abstract" /><meta name="citation_fulltext_html_url" content="/pmc/articles/PMC10357448/" /><meta name="citation_pmid" content="37483220" /><meta name="DC.Title" content="Design of Glycoengineered&#10;IL-4 Antagonists&#10;Employing Chemical and Biosynthetic Glycosylation" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="American Chemical Society" /><meta name="DC.Contributor" content="Sarah Thomas" /><meta name="DC.Contributor" content="Juliane E. Fiebig" /><meta name="DC.Contributor" content="Eva-Maria Kuhn" /><meta name="DC.Contributor" content="Dominik S. Mayer" /><meta name="DC.Contributor" content="Sebastian Filbeck" /><meta name="DC.Contributor" content="Werner Schmitz" /><meta name="DC.Contributor" content="Markus Krischke" /><meta name="DC.Contributor" content="Roswitha Gropp" /><meta name="DC.Contributor" content="Thomas D. Mueller" /><meta name="DC.Date" content="2023 Jul 18" /><meta name="DC.Identifier" content="10.1021/acsomega.3c00726" /><meta name="DC.Language" content="en" /><meta property="og:title" content="Design of Glycoengineered&#10;IL-4 Antagonists&#10;Employing Chemical and Biosynthetic Glycosylation" /><meta property="og:type" content="article" /><meta property="og:description" content="Interleukin-4 (IL-4) plays a key role in atopic diseases.&#10;It coordinates&#10;T-helper cell differentiation to subtype 2, thereby directing defense&#10;toward humoral immunity. Together with Interleukin-13, IL-4 further&#10;induces immunoglobulin class switch to IgE. ..." /><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357448/" /><meta property="og:site_name" content="PubMed Central (PMC)" /><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-card-share.jpg?_=0" /><meta name="twitter:card" content="summary_large_image" /><meta name="twitter:site" content="@ncbi" /><meta name="ncbi_feature" content="associated_data" />


</head>
<body >

   
    
        <button
          class="back-to-top back-to-top--bottom"
          data-ga-category="pagination"
          data-ga-action="back_to_top">
          Back to Top
        </button>
    

    <a class="usa-skipnav" href="#main-content">Skip to main content</a>
    <!-- ========== BEGIN HEADER ========== -->
<section class="usa-banner" style="display: none;">
  <div class="usa-accordion">
    <header class="usa-banner-header">
      <div class="usa-grid usa-banner-inner">
        <img src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png" alt="U.S. flag" />
        <p>An official website of the United States government</p>
        <button
          class="usa-accordion-button usa-banner-button"
          aria-expanded="false"
          aria-controls="gov-banner-top"
        >
          <span class="usa-banner-button-text">Here's how you know</span>
        </button>
      </div>
    </header>
    <div
      class="usa-banner-content usa-grid usa-accordion-content"
      id="gov-banner-top"
    >
      <div class="usa-banner-guidance-gov usa-width-one-half">
        <img
          class="usa-banner-icon usa-media_block-img"
          src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg"
          alt="Dot gov"
        />
        <div class="usa-media_block-body">
          <p>
            <strong>The .gov means it’s official.</strong>
            <br />
            Federal government websites often end in .gov or .mil. Before
            sharing sensitive information, make sure you’re on a federal
            government site.
          </p>
        </div>
      </div>
      <div class="usa-banner-guidance-ssl usa-width-one-half">
        <img
          class="usa-banner-icon usa-media_block-img"
          src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg"
          alt="Https"
        />
        <div class="usa-media_block-body">
          <p>
            <strong>The site is secure.</strong>
            <br />
            The <strong>https://</strong> ensures that you are connecting to the
            official website and that any information you provide is encrypted
            and transmitted securely.
          </p>
        </div>
      </div>
    </div>
  </div>
</section>
<div class="usa-overlay"></div>
<header class="ncbi-header" role="banner" data-section="Header">

	<div class="usa-grid">
		<div class="usa-width-one-whole">

            <div class="ncbi-header__logo">
                <a href="https://www.ncbi.nlm.nih.gov/" class="logo" aria-label="NCBI Logo" data-ga-action="click_image" data-ga-label="NIH NLM Logo">
                  <img src="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg" alt="NIH NLM Logo" />
                </a>
            </div>

			<div class="ncbi-header__account">
				<a id="account_login" href="https://account.ncbi.nlm.nih.gov" class="usa-button header-button" style="display:none" data-ga-action="open_menu" data-ga-label="account_menu">Log in</a>
				<button id="account_info" class="header-button" style="display:none"
						aria-controls="account_popup">
					<span class="fa fa-user" aria-hidden="true"></span>
					<span class="username desktop-only" aria-hidden="true" id="uname_short"></span>
					<span class="sr-only">Show account info</span>
				</button>
			</div>

			<div class="ncbi-popup-anchor">
				<div class="ncbi-popup account-popup" id="account_popup" aria-hidden="true">
					<div class="ncbi-popup-head">
						<button class="ncbi-close-button" data-ga-action="close_menu" data-ga-label="account_menu"><span class="fa fa-times"></span><span class="usa-sr-only">Close</span></button>
						<h4>Account</h4>
					</div>
					<div class="account-user-info">
						Logged in as:<br/>
						<b><span class="username" id="uname_long">username</span></b>
					</div>
					<div class="account-links">
						<ul class="usa-unstyled-list">
							<li><a id="account_myncbi" href="/myncbi/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_myncbi">Dashboard</a></li>
							<li><a id="account_pubs" href="/myncbi/collections/bibliography/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_pubs">Publications</a></li>
							<li><a id="account_settings" href="/account/settings/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_settings">Account settings</a></li>
							<li><a id="account_logout" href="/account/signout/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_logout">Log out</a></li>
						</ul>
					</div>
				</div>
			</div>

		</div>
	</div>
</header>
<div role="navigation" aria-label="access keys">
<a id="nws_header_accesskey_0" href="https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys" class="usa-sr-only" accesskey="0" tabindex="-1">Access keys</a>
<a id="nws_header_accesskey_1" href="https://www.ncbi.nlm.nih.gov" class="usa-sr-only" accesskey="1" tabindex="-1">NCBI Homepage</a>
<a id="nws_header_accesskey_2" href="/myncbi/" class="set-base-url usa-sr-only" accesskey="2" tabindex="-1">MyNCBI Homepage</a>
<a id="nws_header_accesskey_3" href="#maincontent" class="usa-sr-only" accesskey="3" tabindex="-1">Main Content</a>
<a id="nws_header_accesskey_4" href="#" class="usa-sr-only" accesskey="4" tabindex="-1">Main Navigation</a>
</div>
<section data-section="Alerts">
	<div class="ncbi-alerts-placeholder"></div>
</section>
<!-- ========== END HEADER ========== -->

    
    


    
        

<section class="pmc-alerts">
    
    <div role="alert" class="pmc-alert pmc-alert--info" role="region" aria-label="Alert" aria-hidden="false"  data-key="pmc-alert-welcome">
        <div class="pmc-alert__body pmc-alert--ncbi-icon">
            <div class="pmc-alert__content">
                <p>
                    <strong>
                        Preview improvements coming to the PMC website in October 2024.
                        <a href="https://ncbiinsights.ncbi.nlm.nih.gov/2024/03/14/preview-pmc-improvements/" data-ga-category="cloud_beta_banner" data-ga-label="learn_more" data-ga-action="on_pmc2020">Learn More</a> or
                        <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10357448/" data-ga-category="cloud_beta_banner" data-ga-action="on_pmc2020" data-ga-label="go_to_cloud">Try it out now</a>.
                    </strong>
                </p>
            </div>
        </div>
    </div>
    
</section>
    

    
    
        
        <header class="pmc-header usa-header-extended" role="banner">
    <div class="pmc-header__bar">
        <div class="pmc-header__control usa-accordion">
            
                <button class="usa-menu-btn pmc-header--button pmc-header--left">
                    <i class="fa fa-ellipsis-v" aria-hidden="true"></i>
                </button>
            

            <div class="usa-logo pmc-header__logo pmc-header--stretch
                
               " id="extended-mega-logo">
                <div class="usa-logo-text">
                    <a href="/pmc/" title="Home" aria-label="Home" ></a>
                </div>
            </div>
            <button class="usa-accordion-button pmc-header--right pmc-header--button pmc-header__search--control pmc-header--right" aria-expanded="false" aria-controls="a1">
                <i class="fa fa-search" aria-hidden="true"></i>
                <i class="fa fa-times" aria-hidden="true"></i>
            </button>
        </div>
        <div class="pmc-header__search usa-accordion-content" id="a1">
            <div role="search"  class="pmc-header--stretch"  >
    <form class="usa-search " autocomplete="off">
        <div>
              <label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
              <span class="clearable">
                <input
                  required="required"
                  autocomplete-url="/pmc/autocomplete/pmc/"
                  placeholder="Search PMC Full-Text Archive"
                  id="pmc-search" type="search" name="term"/>
                  <i class="clear-btn" ></i>
              </span>
              <button type="submit" formaction="/pmc/">
                <span class="usa-search-submit-text">Search in PMC</span>
              </button>
        </div>
    </form>
</div>


            <ul class="usa-unstyled-list usa-nav-secondary-links pmc-header--offset-two">
                    <li>
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/advanced" data-ga-action="featured_link" data-ga-label="advanced_search">
                            Advanced Search
                        </a>
                    </li>
                    <li>
                        <a  href="/pmc/about/userguide/" data-ga-action="featured_link"
                        data-ga-label="user guide">
                            User Guide
                        </a>
                    </li>
            </ul>
        </div>
    </div>
     <nav role="navigation" class="usa-nav ">
        <button class="usa-nav-close">
            <i class="fa fa-times" aria-hidden="true"></i>
        </button>
        <div class="usa-breadcrumb usa-breadcrumb--wrap usa-breadcrumb--hack">
             
    <ul class="usa-breadcrumb__list">
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/journals/" class="navlink">Journal List</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/journals/3686/">ACS Omega</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/issues/441082/">v.8(28); 2023 Jul 18</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                     aria-current="page" >
                    PMC10357448
                </li>
            
    </ul>
 

        </div>
        
        
            <div class="pmc-sidebar pmc-sidebar-hack">
                

<div class="scroller">

    
        <section>
                <h6>Other Formats</h6>
                <ul class="pmc-sidebar__formats">
                  <li class="pdf-link other_item"><a href="/pmc/articles/PMC10357448/pdf/ao3c00726.pdf" class="int-view">PDF (3.6M)</a></li>
                </ul>
        </section>
    
    <section>
        <h6>Actions</h6>
        <ul class="pmc-sidebar__actions">
            <li>
                <button role="button" class="citation-button citation-dialog-trigger ctxp"
                        aria-label="Open dialog with citation text in different styles" data-ga-category="save_share" data-ga-action="cite" data-ga-label="open"
                        data-all-citations-url="/pmc/resources/citations/10357448/"
                        data-citation-style="nlm"
                        data-download-format-link="/pmc/resources/citations/10357448/export/"
                >
                    <span class="button-label">Cite</span>
                </button>
            </li>
            <li>
                
                    

<link type="text/css" href="ncbi-overlay-block/src/overlay-block.css">
<div class="collections-button-container" data-article-id="10357448" data-article-db="pmc">
  <button class="collections-button collections-dialog-trigger"
          aria-label="Save article in MyNCBI collections."
          data-ga-category="collections_button"
          data-ga-action="click"
          data-ga-label="collections_button"
          data-collections-open-dialog-enabled="false"
          data-collections-open-dialog-url="https://www.ncbi.nlm.nih.gov/account?back_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC10357448%2F%23open-collections-dialog"
          data-in-collections="false">
      <span class="button-label">Collections</span>
  </button>
  <div class="overlay" role="dialog">
  <div id="collections-action-dialog"
       class="dialog collections-dialog"
       aria-hidden="true">
    <div class="title">Add to Collections</div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/pmc/list-existing-collections/"
      data-add-to-existing-collection-url="/pmc/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/pmc/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

  <input type="hidden" name="csrfmiddlewaretoken" value="d9A397gTuTqXwDRLcgTatroHPN2kvzWZKX0aeLVnpLI6E5ox4Tte33sAW5seDmEH">

  

  <div class="choice-group" role="radiogroup">
    <ul class="radio-group-items">
      <li>
        <input type="radio"
               id="collections-action-dialog-new-header "
               class="collections-new"
               name="collections"
               value="new"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_new">
        <label for="collections-action-dialog-new-header ">Create a new collection</label>
      </li>
      <li>
        <input type="radio"
               id="collections-action-dialog-existing-header "
               class="collections-existing"
               name="collections"
               value="existing"
               checked="true"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_existing">
        <label for="collections-action-dialog-existing-header ">Add to an existing collection</label>
      </li>
    </ul>
  </div>

  <div class="controls-wrapper">
    <div class="action-panel-control-wrap new-collections-controls">
      <label for="collections-action-dialog-add-to-new" class="action-panel-label required-field-asterisk">
        Name your collection:
      </label>
      <input
        type="text"
        name="add-to-new-collection"
        id="collections-action-dialog-add-to-new"
        class="collections-action-add-to-new"
        pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
        maxlength=""
        data-ga-category="collections_button"
        data-ga-action="create_collection"
        data-ga-label="non_favorties_collection">
      <div class="collections-new-name-too-long usa-input-error-message selection-validation-message">
        Name must be less than  characters
      </div>
    </div>
    <div class="action-panel-control-wrap existing-collections-controls">
      <label for="collections-action-dialog-add-to-existing" class="action-panel-label">
        Choose a collection:
      </label>
      <select id="collections-action-dialog-add-to-existing"
              class="action-panel-selector collections-action-add-to-existing"
              data-ga-category="collections_button"
              data-ga-action="select_collection"
              data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
      </select>
      <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
        Unable to load your collection due to an error<br>
        <a href="#">Please try again</a>
      </div>
    </div>
  </div>

  <div class="action-panel-actions">
    <button class="action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
      Add
    </button>
    <button class="action-panel-cancel"
            aria-label="Close 'Add to Collections' panel"
            ref="linksrc=close_collections_panel"
            aria-controls="collections-action-panel"
            aria-expanded="false"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="cancel">
      Cancel
    </button>
  </div>
</form>
    </div>
  </div>
</div>
</div>
                
            </li>

        </ul>
    </section>
    
        <section class="social-sharing">
            <h6>Share</h6>
            <ul class="pmc-sidebar__share">
                <li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC10357448%2F&amp;text=Design%20of%20Glycoengineered%0AIL-4%20Antagonists%0AEmploying%20Chemical%20and%20Biosynthetic%20Glycosylation" alt="Share on Twitter"><i class="fa fa-twitter fa-stack-1x">&#160;</i></a></li> 
<li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC10357448%2F" alt="Share on Facebook"><i class="fa fa-facebook fa-stack-1x">&#160;</i></a></li>
                <li>
                    <div class="share-permalink">
                        <button class="trigger"  alt="Show article permalink" aria-expanded="false" aria-haspopup="true">
                            <i class="fa-stack fa-lg" >
                                <i class="fa fa-link fa-stack-1x">&nbsp;</i>
                            </i>
                        </button>
                        <div class="dropdown dropdown-container" hidden>
                              <div class="title">
                                Permalink
                              </div>
                              <div class="content">
                                  <input type="text" class="permalink-text" value="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357448/" aria-label="Article permalink"><button class="permalink-copy-button usa-button-primary" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                                      <span class="button-title">Copy</span>
                                  </button>
                              </div>
                        </div>
                    </div>
                </li>
            </ul>
        </section>
    
    <section>
        <h6>RESOURCES</h6>
        <ul class="pmc-sidebar__resources">
        
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_similar_articles"
                            data-ga-label="/pmc/articles/PMC10357448/"
                            class="usa-accordion-button"
                            aria-controls="similar-articles-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_similar_articles"
                            data-action-close="close_similar_articles"
                    >
                        Similar articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/similar-article-links/37483220/"
                            

                         class="usa-accordion-content pmc-sidebar__resources--citations" id="similar-articles-accordion-header" aria-hidden="true">
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_cited_by"
                            data-ga-label="/pmc/articles/PMC10357448/"
                            class="usa-accordion-button"
                            aria-controls="cited-by-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_cited_by"
                            data-action-close="close_cited_by"
                    >
                        Cited by other articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/cited-by-links/37483220/"
                            
                            class="usa-accordion-content pmc-sidebar__resources--citations"
                            id="cited-by-accordion-header"
                            aria-hidden="true"
                    >
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/pmc/articles/PMC10357448/"
                            class="usa-accordion-button"
                            aria-controls="links-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                    >
                        Links to NCBI Databases
                    </button>
                    <div data-source-url="/pmc/resources/db-links/10357448/" class="usa-accordion-content" id="links-accordion-header" aria-hidden="true"></div>
                </div>
            </li>

            
        
        </ul>
    </section>

 </div>
            </div>
        

    </nav>

</header>

    
    

    <div class="usa-overlay"></div>
    
<main id="main-content" class="usa-grid usa-layout-docs pmc-main">
    <article class="usa-width-three-fourths usa-layout-docs-main_content pmc-article">
        <section class="usa-breadcrumb usa-breadcrumb--wrap">
         
    <ul class="usa-breadcrumb__list">
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/journals/" class="navlink">Journal List</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/journals/3686/">ACS Omega</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/issues/441082/">v.8(28); 2023 Jul 18</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                     aria-current="page" >
                    PMC10357448
                </li>
            
    </ul>
 

        </section>
        
  <div class="pmc-article__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/pmc/about/disclaimer/">PMC Disclaimer</a>
    |
    <a data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/pmc/about/copyright/">
        PMC Copyright Notice
    </a>
</div>

        <section class="pmc-page-banner" role="banner">
            
                
                    <div><img src="/corehtml/pmc/pmcgifs/logo-acsomega.png" alt="Logo of acsomega" usemap="#logo-imagemap" /><map id="logo-imagemap" name="logo-imagemap"><area alt="Link to Publisher's site" title="Link to Publisher's site" shape="default" coords="0,0,499,74" href="https://pubs.acs.org/journal/acsodf" target="_blank" rel="noopener noreferrer" ref="reftype=publisher&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" /></map></div> 
                
            
        </section>
        <section  role="document">
            
                <div id="mc" class=" article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden,.nomenu'"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-flexbox"><div class="fm-citation"><div class="citation-default"><div class="part1"><span id="pmcmata">ACS Omega.</span> 2023 Jul 18; 8(28): 24841–24852. </div><div class="part2"><span class="fm-vol-iss-date">Published online 2023 Jul 5. </span>  <span class="doi"><span>doi: </span><a href="//doi.org/10.1021%2Facsomega.3c00726" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.1021/acsomega.3c00726</a></span></div></div></div><div class="fm-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC10357448</span></div><div class="fm-citation-pmid">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37483220">37483220</a></div></div></div><h1 class="content-title">Design of Glycoengineered
IL-4 Antagonists
Employing Chemical and Biosynthetic Glycosylation</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=Thomas%20S%5BAuthor%5D" id="ath1" class="affpopup" co-rid="_co_idm140686047523424" co-class="co-affbox">Sarah Thomas</a>,<sup>&#x02020;</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Fiebig%20JE%5BAuthor%5D" id="ath2" class="affpopup" co-rid="_co_idm140686054077024" co-class="co-affbox">Juliane E. Fiebig</a>,<sup>&#x02020;</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Kuhn%20EM%5BAuthor%5D" id="ath3" class="affpopup" co-rid="_co_idm140686053146416" co-class="co-affbox">Eva-Maria Kuhn</a>,<sup>&#x02020;</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Mayer%20DS%5BAuthor%5D" id="ath4" class="affpopup" co-rid="_co_idm140686053144192" co-class="co-affbox">Dominik S. Mayer</a>,<sup>&#x02020;</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Filbeck%20S%5BAuthor%5D" id="ath5" class="affpopup" co-rid="_co_idm140686053141968" co-class="co-affbox">Sebastian Filbeck</a>,<sup>&#x02020;</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Schmitz%20W%5BAuthor%5D" id="ath6" class="affpopup" co-rid="_co_idm140686046790768" co-class="co-affbox">Werner Schmitz</a>,<sup>&#x02021;</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Krischke%20M%5BAuthor%5D" id="ath7" class="affpopup" co-rid="_co_idm140686046788544" co-class="co-affbox">Markus Krischke</a>,<sup>&#x000a7;</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Gropp%20R%5BAuthor%5D" id="ath8" class="affpopup" co-rid="_co_idm140686050700176" co-class="co-affbox">Roswitha Gropp</a>,<sup>&#x02225;</sup> and  <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Mueller%20TD%5BAuthor%5D" id="ath9" class="affpopup" co-rid="_co_idm140686050697952" co-class="co-affbox">Thomas D. Mueller</a><sup><img src="/corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author" /></sup><a href="#cor1" rid="cor1" class=" other">*</a><sup>&#x02020;</sup></div><div style="display:none" class="contrib-group aff-tip"><div id="_co_idm140686047523424"><h3 class="no_margin">Sarah Thomas</h3><p><sup>&#x02020;</sup>Department
of Molecular Plant Physiology and Biophysics, Julius-von-Sachs Institute of the University Wuerzburg, Julius-von-Sachs Platz 2, D-97082 Wuerzburg, Germany</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Thomas%20S%5BAuthor%5D">Sarah Thomas</a></div></div><div id="_co_idm140686054077024"><h3 class="no_margin">Juliane E. Fiebig</h3><p><sup>&#x02020;</sup>Department
of Molecular Plant Physiology and Biophysics, Julius-von-Sachs Institute of the University Wuerzburg, Julius-von-Sachs Platz 2, D-97082 Wuerzburg, Germany</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Fiebig%20JE%5BAuthor%5D">Juliane E. Fiebig</a></div></div><div id="_co_idm140686053146416"><h3 class="no_margin">Eva-Maria Kuhn</h3><p><sup>&#x02020;</sup>Department
of Molecular Plant Physiology and Biophysics, Julius-von-Sachs Institute of the University Wuerzburg, Julius-von-Sachs Platz 2, D-97082 Wuerzburg, Germany</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Kuhn%20EM%5BAuthor%5D">Eva-Maria Kuhn</a></div></div><div id="_co_idm140686053144192"><h3 class="no_margin">Dominik S. Mayer</h3><p><sup>&#x02020;</sup>Department
of Molecular Plant Physiology and Biophysics, Julius-von-Sachs Institute of the University Wuerzburg, Julius-von-Sachs Platz 2, D-97082 Wuerzburg, Germany</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Mayer%20DS%5BAuthor%5D">Dominik S. Mayer</a></div></div><div id="_co_idm140686053141968"><h3 class="no_margin">Sebastian Filbeck</h3><p><sup>&#x02020;</sup>Department
of Molecular Plant Physiology and Biophysics, Julius-von-Sachs Institute of the University Wuerzburg, Julius-von-Sachs Platz 2, D-97082 Wuerzburg, Germany</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Filbeck%20S%5BAuthor%5D">Sebastian Filbeck</a></div></div><div id="_co_idm140686046790768"><h3 class="no_margin">Werner Schmitz</h3><p><sup>&#x02021;</sup>Department
of Biochemistry and Molecular Biology, Biocenter
of the University Wuerzburg, Am Hubland, D-97074 Wuerzburg, Germany</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Schmitz%20W%5BAuthor%5D">Werner Schmitz</a></div></div><div id="_co_idm140686046788544"><h3 class="no_margin">Markus Krischke</h3><p><sup>&#x000a7;</sup>Department
of Pharmaceutical Biology, Julius-von-Sachs
Institute of the University Wuerzburg, Julius-von-Sachs Platz 2, D-97082 Wuerzburg, Germany</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Krischke%20M%5BAuthor%5D">Markus Krischke</a></div></div><div id="_co_idm140686050700176"><h3 class="no_margin">Roswitha Gropp</h3><p><sup>&#x02225;</sup>Department
of General- Visceral-, Vascular- and Transplantation Surgery, Hospital of the LMU, Nussbaumstr. 20, 80336 Munich, Germany</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Gropp%20R%5BAuthor%5D">Roswitha Gropp</a></div></div><div id="_co_idm140686050697952"><h3 class="no_margin">Thomas D. Mueller</h3><p><sup>&#x02020;</sup>Department
of Molecular Plant Physiology and Biophysics, Julius-von-Sachs Institute of the University Wuerzburg, Julius-von-Sachs Platz 2, D-97082 Wuerzburg, Germany</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Mueller%20TD%5BAuthor%5D">Thomas D. Mueller</a></div></div></div></div><div class="half_rhythm"><div class="togglers fm-copyright-license"><a href="#" class="pmctoggle" rid="idm140686048897568_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm140686048897568_an">Article notes</a> <a href="#" class="pmctoggle" rid="idm140686048897568_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/" style="margin-left: 1em">PMC Disclaimer</a></div><div class="fm-authors-info hide half_rhythm" id="idm140686048897568_ai" style="display:none"><div class="fm-affl" id="aff1"><sup>&#x02020;</sup>Department
of Molecular Plant Physiology and Biophysics, Julius-von-Sachs Institute of the University Wuerzburg, Julius-von-Sachs Platz 2, D-97082 Wuerzburg, Germany</div><div class="fm-affl" id="aff2"><sup>&#x02021;</sup>Department
of Biochemistry and Molecular Biology, Biocenter
of the University Wuerzburg, Am Hubland, D-97074 Wuerzburg, Germany</div><div class="fm-affl" id="aff3"><sup>&#x000a7;</sup>Department
of Pharmaceutical Biology, Julius-von-Sachs
Institute of the University Wuerzburg, Julius-von-Sachs Platz 2, D-97082 Wuerzburg, Germany</div><div class="fm-affl" id="aff4"><sup>&#x02225;</sup>Department
of General- Visceral-, Vascular- and Transplantation Surgery, Hospital of the LMU, Nussbaumstr. 20, 80336 Munich, Germany</div><div><sup><img src="/corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author" /></sup>Corresponding author.</div><div id="cor1"><sup>*</sup>Email: <a href="mailto:dev@null" data-email="ed.grubzreuw-inu.murtnezoib@relleum" class="oemail">ed.grubzreuw-inu.murtnezoib@relleum</a>.</div></div><div class="fm-article-notes hide half_rhythm" id="idm140686048897568_an" style="display:none"><div class="fm-pubdate half_rhythm">Received 2023 Feb 3; Accepted 2023 Jun 13.</div></div><div class="permissions half_rhythm hide" id="idm140686048897568_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">Copyright</a> &#x000a9; 2023 The Authors. Published by American Chemical Society</div><div class="license half_rhythm">Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (<a href="https://creativecommons.org/licenses/by/4.0/" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CFront%20Matter&amp;TO=External%7CLink%7CURI" target="_blank">https://creativecommons.org/licenses/by/4.0/</a>).</div></div></div><div id="pmclinksbox" class="links-box whole_rhythm hidden" role="complementary" aria-label="Related or updated information about this article."></div></div><div class="sec"></div><div id="ass-data" class="tsec fm-sec whole_rhythm" data-section="Featured_PMC_Datacitation"><h2 class="nomenu">Associated Data</h2><dl data-count="1" class="box-data-suppmats whole_rhythm no_bottom_margin"><dt><a href="#" rid="data-suppmats" data-ga-action="click_feat_toggler" data-ga-label="Supplementary Materials" class="pmctoggle">Supplementary Materials</a></dt><dd id="data-suppmats" style="display: none;"><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin">ao3c00726_si_001.pdf</div><div><a href="/pmc/articles/PMC10357448/bin/ao3c00726_si_001.pdf" data-ga-action="click_feat_suppl">ao3c00726_si_001.pdf</a><span style="color:gray"> (11M)</span></div><div class="small guid">GUID: 9F8E5506-4324-4A4D-A928-5908FB49671F</div></div></dd></dl></div><div id="abstract-a.q.b.n" lang="en" class="tsec sec"><h2 class="head no_bottom_margin" id="abstract-a.q.b.ntitle">Abstract</h2><!--article-meta--><div><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140686092441552"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10357448_ao3c00726_0008.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is ao3c00726_0008.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC10357448/bin/ao3c00726_0008.jpg" /></a></div><p></p><p class="p p-last">Interleukin-4 (IL-4) plays a key role in atopic diseases.
It coordinates
T-helper cell differentiation to subtype 2, thereby directing defense
toward humoral immunity. Together with Interleukin-13, IL-4 further
induces immunoglobulin class switch to IgE. Antibodies of this type
activate mast cells and basophilic and eosinophilic granulocytes,
which release pro-inflammatory mediators accounting for the typical
symptoms of atopic diseases. IL-4 and IL-13 are thus major targets
for pharmaceutical intervention strategies to treat atopic diseases.
Besides neutralizing antibodies against IL-4, IL-13, or its receptors,
IL-4 antagonists can present valuable alternatives. Pitrakinra, an <em>Escherichia coli</em>-derived IL-4 antagonist, has been
evaluated in clinical trials for asthma treatment in the past; however,
deficits such as short serum lifetime and potential immunogenicity
among others stopped further development. To overcome such deficits,
PEGylation of therapeutically important proteins has been used to
increase the lifetime and proteolytic stability. As an alternative,
glycoengineering is an emerging strategy used to improve pharmacokinetics
of protein therapeutics. In this study, we have established different
strategies to attach glycan moieties to defined positions in IL-4.
Different chemical attachment strategies employing thiol chemistry
were used to attach a glucose molecule at amino acid position 121,
thereby converting IL-4 into a highly effective antagonist. To enhance
the proteolytic stability of this IL-4 antagonist, additional glycan
structures were introduced by glycoengineering utilizing eucaryotic
expression. IL-4 antagonists with a combination of chemical and biosynthetic
glycoengineering could be useful as therapeutic alternatives to IL-4
neutralizing antibodies already used to treat atopic diseases.</p></div></div><div id="sec1" class="tsec sec"><h2 class="head no_bottom_margin" id="sec1title">Introduction</h2><p class="p p-first">Interleukin (IL)-4 is produced by hematopoietic
cells and exerts
multiple effects on the immune system. One major function is the regulation
of T-helper cell development, where it triggers the differentiation
of na&#x000ef;ve CD4<sup>+</sup> T-helper cells (Th0) into subtype
2 T-helper cells (Th2).<sup><a href="#ref1" rid="ref1" class=" bibr popnode">1</a>&#x02212;<a href="#ref4" rid="ref4" class=" bibr popnode">4</a></sup> Mature Th2-cells secrete a specific subset of cytokines, including
IL-4, IL-5, and IL-13 that mediate an inflammatory immune response
against extracellular pathogens.<sup><a href="#ref5" rid="ref5" class=" bibr popnode">5</a></sup> By secreting
IL-4, Th2-cells suppress the development of the Th1 phenotype thereby
maintaining Th2 cell activity.<sup><a href="#ref6" rid="ref6" class=" bibr popnode">6</a>,<a href="#ref7" rid="ref7" class=" bibr popnode">7</a></sup> Physiological effects
of IL-4 and IL-13 partially overlap. Both cytokines induce the upregulation
of vascular cell adhesion molecule-1 (VCAM1) and thus facilitate leukocyte
migration to the site of infection.<sup><a href="#ref8" rid="ref8" class=" bibr popnode">8</a>,<a href="#ref9" rid="ref9" class=" bibr popnode">9</a></sup> Most importantly,
IL-4 and IL-13 drive immunoglobulin class switching to immunoglobulin
E (IgE) in B-cells.<sup><a href="#ref10" rid="ref10" class=" bibr popnode">10</a>,<a href="#ref11" rid="ref11" class=" bibr popnode">11</a></sup> In addition, IL-4 and IL-13 upregulate
Fc&#x003b5;-receptors on <em>e.g.</em>, mast cells and B-cells.<sup><a href="#ref12" rid="ref12" class=" bibr popnode">12</a>&#x02212;<a href="#ref15" rid="ref15" class=" bibr popnode">15</a></sup> IL-4/IL-13-mediated IgE sensitization is of great pathophysiological
significance, as IgE plays a major role in atopic diseases, such as
asthma, atopic dermatitis, and allergic rhinitis.<sup><a href="#ref16" rid="ref16" class=" bibr popnode">16</a></sup> The recognition of allergens through the IgE/Fc&#x003b5;
complex on mast cells and basophilic or eosinophilic granulocytes
stimulates their degranulation leading to the release of pro-inflammatory
mediators, like the anticoagulant heparin and the vasodilator histamine.
Prostaglandins, leukotrienes, and proteases are also released, facilitating
local inflammation by causing muscle constriction and tissue remodeling.<sup><a href="#ref17" rid="ref17" class=" bibr popnode">17</a></sup> Their crucial role in the pathophysiology of
atopic diseases has made both cytokines, IL-4 and IL-13, key targets
for novel therapeutic approaches to fight allergies and asthma.<sup><a href="#ref18" rid="ref18" class=" bibr popnode">18</a></sup></p><p class="p p-last">IL-4 and IL-13 share a set of transmembrane
receptors, which upon
ligand-mediated activation induce the JAK/STAT signaling cascade.<sup><a href="#ref19" rid="ref19" class=" bibr popnode">19</a></sup> IL-4 can form two heterodimeric receptor assemblies,
termed interleukin-4 type I and type II receptors. In a sequential
process, IL-4 first binds to IL-4 receptor &#x003b1; (IL-4R&#x003b1;)
(CD124) and this membrane-located complex then recruits one of the
two other receptors, either the so-called common &#x003b3; chain (short:
&#x003b3;c; CD132) forming the IL-4 type I receptor, or IL-13R&#x003b1;1
(CD213a1) to yield the IL-4 type II receptor.<sup><a href="#ref20" rid="ref20" class=" bibr popnode">20</a></sup> The type I receptor is activated exclusively by IL-4, although &#x003b3;c
itself is shared with other cytokines IL-2, IL-7, IL-9, IL-15, and
IL-21.<sup><a href="#ref21" rid="ref21" class=" bibr popnode">21</a></sup> The IL-4 type II receptor is used
by IL-4 and IL-13 and hence both cytokines assemble and activate the
same receptor, explaining their overlapping functions. This receptor
sharing allows simultaneous inhibition of both cytokines by targeting
the common receptor IL-4R&#x003b1;.<sup><a href="#ref22" rid="ref22" class=" bibr popnode">22</a></sup> As
a classical approach, anti-IL-4R&#x003b1; antibodies, AMG317 (Amgen)
and Dupilumab (Regeneron/Sanofi), have been developed which simultaneously
neutralize IL-4 and IL-13 signaling.<sup><a href="#ref23" rid="ref23" class=" bibr popnode">23</a></sup> Dupilumab
was approved for treatment of atopic dermatitis, thereby confirming
IL-4R&#x003b1; as a therapeutic target for atopic diseases.<sup><a href="#ref24" rid="ref24" class=" bibr popnode">24</a>,<a href="#ref25" rid="ref25" class=" bibr popnode">25</a></sup> A second, non-antibody-based strategy to inhibit IL-4 and IL-13
has been implemented employing a mechanistically similar approach
to that for Dupilumab. From mutagenesis two positions in IL-4 were
shown to convert IL-4 into an effective antagonist that binds IL-4R&#x003b1;
with wild-type-like affinity, but is incapable of activating either
the type I or type II receptor as it cannot bind &#x003b3;c or IL-13R&#x003b1;1.<sup><a href="#ref26" rid="ref26" class=" bibr popnode">26</a>&#x02212;<a href="#ref28" rid="ref28" class=" bibr popnode">28</a></sup> This IL-4 variant harboring mutations R121D and Y124D was termed
Pitrakinra. It was tested for application in allergic asthma until
clinical phase trial 2a, where it failed to meet endpoint criteria.
Further developments of Pitrakinra were stopped, although positive
therapeutic effects, <em>e.g.</em>, fewer allergen-induced
exacerbations, could be observed.<sup><a href="#ref29" rid="ref29" class=" bibr popnode">29</a></sup> A major
disadvantage seemed its very short half-life <em>in vivo</em> due to the small size and lack of glycosylation, resulting from
its production in prokaryotic expression systems.<sup><a href="#ref30" rid="ref30" class=" bibr popnode">30</a></sup> To overcome these problems short PEGylation was tested.
However, even though PEG coupling was done site-specific, the modification
significantly impaired inhibitor efficacy.<sup><a href="#ref31" rid="ref31" class=" bibr popnode">31</a></sup> Here, we present an alternative to Pitrakinra, which evades its
inherent disadvantages using a novel approach to simultaneously implement
IL-4 antagonism and improve its pharmacological properties.</p></div><div id="sec2" class="tsec sec"><h2 class="head no_bottom_margin" id="sec2title">Results</h2><div id="sec2.1" class="sec sec-first"><h3 id="sec2.1title">New Strategy to Generate an IL-4 Antagonist &#x02013; Glycan-Mediated
Steric Hindrance</h3><p class="p p-first">Pitrakinra exerts its antagonistic effect
by introducing an electrostatic mismatch in the binding epitopes to
&#x003b3;c and IL-13R&#x003b1;1.<sup><a href="#ref32" rid="ref32" class=" bibr popnode">32</a></sup> We hypothesized
that implementing steric hindrance instead might yield a superior
antagonist, as binding to &#x003b3;c or IL-13R&#x003b1;1 can be more effectively
blocked. Duppatla et al. coupled thiol-reactive, bulky reagents to
cysteine residues introduced in IL-4&#x02032;s binding epitope for
&#x003b3;c and IL-13R&#x003b1;1 to induce steric hindrance.<sup><a href="#ref33" rid="ref33" class=" bibr popnode">33</a>,<a href="#ref34" rid="ref34" class=" bibr popnode">34</a></sup> They found that the site-specific modification of a single IL-4
residue, i.e., Arg121 is sufficient to disrupt binding to &#x003b3;c
and IL-13R&#x003b1;1. However, the authors used either maleimide-containing
molecules, <em>e.g.</em>, N-ethylmaleimide, that might be
immunogenic when presented by IL-4 in a hapten-like manner or large
polymers such as PEG, which are heterogeneous and can negatively influence
antagonist efficacy due to their sheer size as seen for PEGylated
Pitrakinra.<sup><a href="#ref31" rid="ref31" class=" bibr popnode">31</a></sup> In addition, PEG shows poor
degradability leading to accumulation in the liver and in some, albeit
in rare cases anti-PEG antibodies were detected that would invalidate
the therapeutic.<sup><a href="#ref35" rid="ref35" class=" bibr popnode">35</a></sup> For the development
of an improved IL-4 antagonist we therefore wanted to use modifications
to introduce steric hindrance, which are naturally present on the
human IL-4 protein surface. Glycosylation is a native modification
found in many secreted proteins, which can decrease immunogenicity
and prolong the serum half-life.<sup><a href="#ref36" rid="ref36" class=" bibr popnode">36</a>,<a href="#ref37" rid="ref37" class=" bibr popnode">37</a></sup></p><p class="p p-last">We first
tested whether an N-glycan moiety can be installed at position 121
by mutating the target site to encode an N-glycosylation motif, i.e.,
Asn121-Glu122-Ser123. To facilitate analysis, the native N-glycosylation
site in IL-4 at Asn38 was silenced,<sup><a href="#ref38" rid="ref38" class=" bibr popnode">38</a></sup> i.e.,
via mutation N38Q, thereby generating a variant with a single potential
N-glycosylation site. Expression in HEK293 cells, however, revealed
that the engineered site was not modified (see <a href="https://pubs.acs.org/doi/suppl/10.1021/acsomega.3c00726/suppl_file/ao3c00726_si_001.pdf" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Figure S1</a>). This suggests that introducing a glycan moiety
at position 121 requires a post-translational chemical procedure and
cannot be achieved by biosynthetic means.</p></div><div id="sec2.2" class="sec"><h3 id="sec2.2title">Coupling of a Carbohydrate to Position 121 via a Bifunctional
Chemical Crosslinker</h3><p class="p p-first">For chemical coupling, we introduced
a thiol group as the reactive site for several reasons (see also ref (<a href="#ref39" rid="ref39" class=" bibr popnode">39</a>)). As IL-4 does not contain
any unpaired cysteine,<sup><a href="#ref38" rid="ref38" class=" bibr popnode">38</a></sup> the introduced
thiol group will allow site-specific coupling. Second, thiol coupling
can be performed under near-physiological conditions. Conjugation
occurs fast and unspecific reaction with other polar groups in proteins
is not observed. We used prokaryotic expression to produce IL-4 in
insoluble form in so-called inclusion bodies. After extraction, an
oxidative <em>in vitro</em> refolding is performed to obtain
IL-4 in its native fold with all three native disulfide bonds formed.
All variants contained the mutation F82D as this mutation enhances
the affinity for IL-4R&#x003b1; about 3-fold,<sup><a href="#ref40" rid="ref40" class=" bibr popnode">40</a></sup> which enables the IL-4 antagonist to more effectively outcompete
endogenous wild-type IL-4. After expression in <em>Escherichia
coli</em>, the IL-4 F82D R121C protein was extracted, and <em>in vitro</em> refolding was performed using a glutathione-based
redox couple to facilitate disulfide formation. Under this condition,
the unpaired cysteine (Cys121) formed a mixed disulfide with glutathione.
While this protects from non-specific side reactions, subsequent removal
of this &#x0201c;protection&#x0201d; group is required before carbohydrate
coupling can proceed. Removal of this glutathionyl group by chemical
reduction failed, as all reducing agents tested also simultaneously
cleaved IL-4&#x02019;s native disulfide bonds. This led to denaturation
and irreversible precipitation of the protein. For specific removal,
Duppatla et al. developed an enzymatic procedure utilizing <em>E. coli</em> GSH-disulfide oxidoreductase glutaredoxin-1
(grxA).<sup><a href="#ref33" rid="ref33" class=" bibr popnode">33</a></sup> In the presence of reduced glutathione
(GSH) the enzyme preferentially reduces the mixed glutathione-disulfide.
It therefore generates a free thiol group at the unpaired cysteine
and oxidized glutathione (GSSG). As the latter inhibits glutaredoxin,
GSSG must be recycled using glutathione reductase and NADPH. Although
glutaredoxin-1 preferentially cleaves GSH-Cys mixed disulfides, it
can also reduce regular cystine disulfide bonds albeit at a slower
rate. Hence reaction times and GSH concentration for enzymatic removal
of glutathione from mixed disulfides had to be optimized. For IL-4
F82D R121C, a reaction time of 2.5 min was sufficient to achieve nearly
complete conversion of Cys121 into its non-conjugated, free thiol
form, longer reaction times led to enhanced cleavage of IL-4&#x02019;s
native disulfide bonds, shorter reaction times did not sufficiently
cleave the GSH-Cys mixed disulfide bond (<a href="https://pubs.acs.org/doi/suppl/10.1021/acsomega.3c00726/suppl_file/ao3c00726_si_001.pdf" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Figure S2A,B</a>). The protein could be recovered in high purity with
about 50&#x02013;60% yield. Subsequent oxidation of the thiol group
was prevented by acidifying the protein solution to pH &#x02264; 6.</p><p>As the composition and architecture of the carbohydrate to be coupled
affect parameters, such as immunogenicity, stability, and serum half-life,
we first developed a coupling scheme for complex glycans isolated
from natural protein sources. The latter could be obtained by enzymatic
hydrolysis using endoglycosidase PNGase F, which yields complex glycans
with a 1-amino-&#x003b2;-GlcNAc form at the reducing end. Coupling of
such an amino-saccharide to a thiol requires a (hetero)-bifunctional
chemical crosslinker equipped with a thiol-reactive as well as an
amino-reactive group (<a href="/pmc/articles/PMC10357448/figure/fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig1" rid-ob="ob-fig1" co-legend-rid="lgnd_fig1"><span>Figure <a href="/pmc/articles/PMC10357448/figure/fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig1" rid-ob="ob-fig1" co-legend-rid="lgnd_fig1"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure1</span></span><span>1</span></a></span></a>). The reaction can be performed under near-physiological
conditions but requires a defined sequential procedure due to other
reactive amino groups (<em>e.g.</em>, lysine) in the protein,
which would form unwanted conjugates. Succinimidyl 4-(<em>N</em>-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) was chosen as
the crosslinker as the cyclohexane ring restrains the conformational
freedom required to establish steric hindrance for conversion of IL-4
into an antagonist.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="fig1" co-legend-rid="lgnd_fig1"><a href="/pmc/articles/PMC10357448/figure/fig1/" target="figure" rid-figpopup="fig1" rid-ob="ob-fig1"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140686050013792"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10357448_ao3c00726_0002.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is ao3c00726_0002.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC10357448/bin/ao3c00726_0002.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140686050013792"><a target="object" rel="noopener" href="/pmc/articles/PMC10357448/figure/fig1/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_fig1"><div><a class="figpopup" href="/pmc/articles/PMC10357448/figure/fig1/" target="figure" rid-figpopup="fig1" rid-ob="ob-fig1">Figure 1</a></div><!--caption a7--><div class="caption"><p>Conjugation of amino sugars to the thiol group in IL-4
F82D R121C
employing the bifunctional crosslinker SMCC. (A) Bacterial expression
and oxidative refolding of IL-4 variants harboring an unpaired cysteine
in the presence of a glutathione redox couple. (B) Enzymatic deglutathionylation
of the mixed glutathione-disulfide bond using the glutaredoxin system
yielding a free thiol group at the engineered cysteine. (C) Reaction
of the bifunctional crosslinker SMCC with glucosamine. (D) Site-specific
conjugation of the SMCC-glucosamine conjugate to the thiol group of
the engineered cysteine.</p></div></div></div><p class="p p-last">Since the availability of complex glycans is limited,
a proof-of-concept
study was performed using 2-glucosamine-HCl, which carries an amino
group at C-atom 2 (<a href="https://pubs.acs.org/doi/suppl/10.1021/acsomega.3c00726/suppl_file/ao3c00726_si_001.pdf" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Table S1</a>). First, the
glucosamine&#x02013;SMCC conjugate was prepared to prevent conjugation
of the SMCC NHS-activated carboxylate group to amino groups in IL-4.
SMCC was coupled to 2-glucosamine-HCl in a molar ratio of 1:4. Mass
spectrometry analysis (for experimental procedure see the <a href="https://pubs.acs.org/doi/suppl/10.1021/acsomega.3c00726/suppl_file/ao3c00726_si_001.pdf" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Supporting Information</a>), however, revealed a
low conversion yield, demanding efficient purification of the conjugate
to avoid the presence of amino-reactive, non-coupled SMCC in the subsequent
reaction with IL-4. Reversed-phase chromatography was used due to
the high hydrophobicity of SMCC, which decreased upon coupling to
glucosamine. Both products could be separated with SMCC-glucosamine
elution at 55% acetonitrile and non-reacted SMCC at &#x02265;90% acetonitrile
(<a href="https://pubs.acs.org/doi/suppl/10.1021/acsomega.3c00726/suppl_file/ao3c00726_si_001.pdf" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Figure S3</a>). Using the above-described
setup the overall yield of the conjugate was about 5% only based on
SMCC as an educt. The low coupling yield might be partly related due
to the low pH of the coupling reaction since dissolving glucosamine-HCl
in phosphate buffer at the given concentrations resulted in a shift
in the pH of the reaction mixture to 6.5, possibly too low for efficient
coupling of the amine to the N-hydroxysuccinimide activated carboxylate
group in SMCC. We therefore, tried to optimize the first coupling
step, however, reaction conditions for this coupling reaction with
SMCC are rather limited. While a more basic pH can increase the efficiency
of the amino coupling reaction through the activated NHS ester group,
a pH value of the reaction mixture above 7.5 will lead to unspecific
(competitive) coupling of amines to the maleimide group.<sup><a href="#ref41" rid="ref41" class=" bibr popnode">41</a></sup> In addition, at basic pH maleimide groups suffer
fast hydrolysis, which would impede the second coupling of the glucose-crosslinker
adduct to IL-4.<sup><a href="#ref41" rid="ref41" class=" bibr popnode">41</a></sup> To limit hydrolysis,
we have chosen SMCC as a bifunctional crosslinker, in which the cyclohexane
ring stabilizes the adjacent maleimide group.<sup><a href="#ref42" rid="ref42" class=" bibr popnode">42</a></sup> This, however, strongly decreases the solubility of the crosslinker
as well as of the glucosamine-SMMC product hampering subsequent purification
efforts. Alternative coupling conditions were tested employing a pH
value of 7.2 (measured in the reaction mixture) for the first coupling
step and testing dimethyl sulfoxide instead of acetonitrile as the
solvent for SMCC. Despite these efforts coupling of glucosamine to
SMCC did not exceed a yield of more than 25&#x02013;30%. An alternative
synthesis route, <em>e.g.</em>, first coupling SMCC to the
IL-4 protein is also not possible though. Due to the large number
of lysine residues in the protein, the conjugation of the SMCC crosslinker
to IL-4 would result in significant coupling of SMCC to these amine
groups instead of the desired conjugation to the introduced cysteine
residue. The highly purified glucosamine-SMCC conjugate derived from
the above-described reaction was then reacted for 2 h at room temperature
(RT) with enzymatically deglutathionylated IL-4 F82D R121C using a
molar ratio of 100:1 and the reaction setup was purified by reversed-phase
high-performance liquid chromatography (RP-HPLC) (<a href="https://pubs.acs.org/doi/suppl/10.1021/acsomega.3c00726/suppl_file/ao3c00726_si_001.pdf" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Figure S4</a>). Mass spectrometry confirmed that this procedure
afforded the desired protein glycoconjugate and coupling to Cys121
occurred specifically (<a href="https://pubs.acs.org/doi/suppl/10.1021/acsomega.3c00726/suppl_file/ao3c00726_si_001.pdf" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Table S2 and Figure S5</a>). While the second coupling step could be performed with a high
conversion rate, the overall strategy is seriously handicapped by
the low yield for the first SMCC-carbohydrate coupling reaction and
hence this strategy was not developed any further.</p></div><div id="sec2.3" class="sec"><h3 id="sec2.3title">Linker-Free Coupling of Thiol-Carbohydrates Using Phenylselenyl
Bromide Activation</h3><p class="p p-first">Hence, a different approach was developed,
which allows direct/linker-free conjugation of a carbohydrate moiety
to engineered cysteine residues. A glycoengineering strategy, established
by Gamblin and colleagues termed Glyco-SeS,<sup><a href="#ref43" rid="ref43" class=" bibr popnode">43</a></sup> utilizes thiol-functionalized carbohydrates (see <a href="https://pubs.acs.org/doi/suppl/10.1021/acsomega.3c00726/suppl_file/ao3c00726_si_001.pdf" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Table S1</a>) for linker-free conjugation. Reaction with a phenylselenylating
reagent converts the free sulfhydryl group into a mixed phenylselenylsulfide.<sup><a href="#ref43" rid="ref43" class=" bibr popnode">43</a>&#x02212;<a href="#ref45" rid="ref45" class=" bibr popnode">45</a></sup> Because of the electrophilic nature of sulfur in this S&#x02013;Se
bond, it readily reacts with thiol-containing carbohydrates to form
disulfide-linked protein&#x02013;carbohydrate conjugates (<a href="/pmc/articles/PMC10357448/figure/fig2/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig2" rid-ob="ob-fig2" co-legend-rid="lgnd_fig2"><span>Figure <a href="/pmc/articles/PMC10357448/figure/fig2/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig2" rid-ob="ob-fig2" co-legend-rid="lgnd_fig2"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure2</span></span><span>2</span></a></span></a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="fig2" co-legend-rid="lgnd_fig2"><a href="/pmc/articles/PMC10357448/figure/fig2/" target="figure" rid-figpopup="fig2" rid-ob="ob-fig2"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140686094963376"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10357448_ao3c00726_0003.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is ao3c00726_0003.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC10357448/bin/ao3c00726_0003.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140686094963376"><a target="object" rel="noopener" href="/pmc/articles/PMC10357448/figure/fig2/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_fig2"><div><a class="figpopup" href="/pmc/articles/PMC10357448/figure/fig2/" target="figure" rid-figpopup="fig2" rid-ob="ob-fig2">Figure 2</a></div><!--caption a7--><div class="caption"><p>Conjugation of thiol-carbohydrates
to IL-4 F82D R121C using phenylselenyl
bromide activation. (A) Bacterial expression and oxidative refolding
of IL-4 variants harboring unpaired cysteine in the presence of a
glutathione redox couple. (B) Enzymatic reduction of the glutathione-mixed
disulfide using the glutaredoxin system yielding engineered cysteine
with a free thiol. (C) Activation of the free thiol of the engineered
cysteine with phenylselenyl bromide to yield mixed phenylselenylsulfide.
(D) Conjugation of the thiol-carbohydrate, yielding a disulfide-linked
glycoprotein conjugate.</p></div></div></div><p>Alternatively, thio-carbohydrates can be activated
with phenylselenyl
bromide, which is then coupled to a free thiol in the protein. The
approach is also applicable to glycans isolated from natural sources,
although the polysaccharide has to be thiol-functionalized prior to
coupling, <em>e.g.</em>, through reaction with Lawesson&#x02032;s
reagent.<sup><a href="#ref44" rid="ref44" class=" bibr popnode">44</a></sup></p><p class="p p-last">To test this approach
commercially available 1-thio-&#x003b2;-<span class="small-caps">d</span>-glucose sodium salt
and the acetylated derivative 1-thio-&#x003b2;-<span class="small-caps">d</span>-glucose tetraacetate
were used as model substrates. Deglutathionylated
IL-4 F82D R121C was treated with a 40-fold molar excess of phenylselenyl
bromide for 1 h. After the removal of excess phenylselenyl bromide
by size exclusion, the &#x0201c;thiol-activated&#x0201d; protein was
reacted with an 80-fold molar excess of thio-glucose for 40 min at
RT. Unfortunately, no full conversion could be achieved and mass spectrometry
revealed about 10% non-modified IL-4 F82D R121C. Because non-conjugated
IL-4 F82D R121C exerts agonistic activity,<sup><a href="#ref34" rid="ref34" class=" bibr popnode">34</a></sup> it must be removed. Non-conjugated IL-4 F82D R121C could be efficiently
removed by covalent binding to iodoacetyl-activated agarose due to
its reactive thiol group (see the <a href="https://pubs.acs.org/doi/suppl/10.1021/acsomega.3c00726/suppl_file/ao3c00726_si_001.pdf" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Supporting Information</a>). Thereby, pure IL-4 F82D R121C-SS-(4ac)Glc and IL-4 F82D R121C-SS-Glc
were obtained (<a href="https://pubs.acs.org/doi/suppl/10.1021/acsomega.3c00726/suppl_file/ao3c00726_si_001.pdf" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Figure S6</a>). Thus, the Glyco-SeS
method can be used for crosslinker-free preparation of disulfide-linked
IL-4 glycoproteins. However, a large excess of thio-carbohydrates
is needed, conversion was nonetheless incomplete, and removal of non-modified
protein was necessary. In addition, enzymatic deglutathionylation
of the engineered cysteine is still a prerequisite, which potentially
limits large-scale synthesis.</p></div><div id="sec2.4" class="sec"><h3 id="sec2.4title">Direct Coupling of Thiol-Carbohydrates during Refolding of IL-4</h3><p class="p p-first">Refolding of bacteria-derived IL-4 is done with a glutathione GSH/GSSG
redox couple to facilitate disulfide bond formation and to improve
the yield of the correctly folded protein. We thus wondered whether
disulfide-linked IL-4 glycoconjugates could be generated by adding
thio-carbohydrates instead of glutathione to refolding (<a href="/pmc/articles/PMC10357448/figure/fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig3" rid-ob="ob-fig3" co-legend-rid="lgnd_fig3"><span>Figure <a href="/pmc/articles/PMC10357448/figure/fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig3" rid-ob="ob-fig3" co-legend-rid="lgnd_fig3"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure3</span></span><span>3</span></a></span></a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="fig3" co-legend-rid="lgnd_fig3"><a href="/pmc/articles/PMC10357448/figure/fig3/" target="figure" rid-figpopup="fig3" rid-ob="ob-fig3"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140686090164784"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10357448_ao3c00726_0004.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is ao3c00726_0004.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC10357448/bin/ao3c00726_0004.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140686090164784"><a target="object" rel="noopener" href="/pmc/articles/PMC10357448/figure/fig3/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_fig3"><div><a class="figpopup" href="/pmc/articles/PMC10357448/figure/fig3/" target="figure" rid-figpopup="fig3" rid-ob="ob-fig3">Figure 3</a></div><!--caption a7--><div class="caption"><p>Conjugation of thiol-carbohydrates
to IL-4 F82D R121C during refolding.
Bacterial expression and oxidative refolding of IL-4 cysteine variants
in the presence of thiol-carbohydrate.</p></div></div></div><p>IL-4 F82D R121C was extracted from inclusion bodies
and the protein
solution was added to renaturation buffer to yield a protein concentration
of 50 &#x003bc;g/mL. Refolding was performed in the presence of 1 M
arginine and 1 mM 1-&#x003b2; thio-glucose (or its tetraacetate derivative).
Although no oxidizing GSSG was present, the refolding yield was identical
to conditions containing a glutathione redox couple (about 10 mg IL-4/g <em>E. coli</em> biomass). Mass spectrometry verified that
all three native disulfide bonds were correctly formed and that Cys121
was disulfide-bonded to glucose (or its tetraacetate derivative) with
no non-conjugated protein present (<a href="https://pubs.acs.org/doi/suppl/10.1021/acsomega.3c00726/suppl_file/ao3c00726_si_001.pdf" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Figure S5</a>).</p><p class="p p-last">The scheme was then tested for whether it is limited to
single-site
glycoconjugation or whether multiple thio-saccharides can be coupled
to IL-4 variants carrying several unpaired cysteines. For proof of
principle, variant F82D R121C N38C was generated containing a second
unpaired cysteine at position 38. Refolding was performed as above,
delivering the same yield as for the IL-4 single-site conjugate F82D
R121C. Mass spectrometry identified one major species with the molecular
weight of IL-4 F82D R121C N38C comprising three disulfide bonds and
with both engineered cysteines conjugated to thio-glucose (or its
tetraacetate derivative) (<a href="https://pubs.acs.org/doi/suppl/10.1021/acsomega.3c00726/suppl_file/ao3c00726_si_001.pdf" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Figure S5</a>). In
contrast to IL-4 F82D R121C, also non-modified and IL-4 F82D R121C
N38C, conjugated only at one site, were obtained, indicating that
conjugation of thio-saccharides to several sites likely requires adjustment
of reaction conditions for full conversion (<a href="https://pubs.acs.org/doi/suppl/10.1021/acsomega.3c00726/suppl_file/ao3c00726_si_001.pdf" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Figure S5</a>). This hypothesis is corroborated by the finding that the
bulkier tetraacetate thio-glucose showed a lower coupling rate than
the smaller thio-glucose.</p></div><div id="sec2.5" class="sec"><h3 id="sec2.5title">Glycoengineered IL-4 F82D R121C Variants Exhibit High-Affinity
for IL-4R&#x003b1; and act as Highly Effective IL-4 Antagonists in Cell-Based
Assays</h3><p class="p p-first">To test whether thio-saccharide coupling to IL-4 R121C
affects binding to the receptor IL-4R&#x003b1;, which would deteriorate
antagonist efficacy, surface plasmon resonance (SPR) (see the <a href="https://pubs.acs.org/doi/suppl/10.1021/acsomega.3c00726/suppl_file/ao3c00726_si_001.pdf" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Supporting Information</a>) was used to determine
affinities of glycoengineered IL-4 F82D R121C analogues for IL-4R&#x003b1;.
Analysis of the SPR sensograms (<a href="https://pubs.acs.org/doi/suppl/10.1021/acsomega.3c00726/suppl_file/ao3c00726_si_001.pdf" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Figure S7</a>) yielded an apparent affinity of 183&#x000b1;42 pM for wild-type IL-4
(non-modified and not containing the IL-4R&#x003b1; affinity-enhancing
mutation F82D), consistent with previous reports.<sup><a href="#ref34" rid="ref34" class=" bibr popnode">34</a>,<a href="#ref40" rid="ref40" class=" bibr popnode">40</a>,<a href="#ref46" rid="ref46" class=" bibr popnode">46</a></sup> IL-4 F82D R121C variants conjugated to different
carbohydrate moieties similarly exhibited high-affinity binding to
IL-4R&#x003b1;, which exceeded those of wild-type IL-4 and Pitrakinra
by about 9 to 10-fold (<a href="#tbl1" rid="tbl1" class=" other">Table <a href="#tbl1" rid="tbl1" class=" other">1</a></a>).</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap anchored whole_rhythm" id="tbl1"><h3>Table 1</h3><!--caption a7--><div class="caption"><!--caption a8--><strong>SPR Analysis of IL-4 Variants and
Glycoconjugates<sup>a</sup></strong></div><div class="xtable"><table frame="hsides" rules="groups" border="0" class="rendered small default_table"><thead><tr><th style="border:none;" align="center" rowspan="1" colspan="1">IL-4 variant</th><th style="border:none;" align="center" rowspan="1" colspan="1"><em>k</em><sub>off</sub>&#x000a0;&#x000d7;&#x000a0;10<sup>&#x02013;4</sup>&#x000a0;[s<sup>&#x02013;1</sup>]</th><th style="border:none;" align="center" rowspan="1" colspan="1"><em>k</em><sub>on</sub>&#x000a0;&#x000d7;&#x000a0;10<sup>6</sup>&#x000a0;[M<sup>&#x02013;1</sup>&#x000a0;s<sup>&#x02013;1</sup>]</th><th style="border:none;" align="center" rowspan="1" colspan="1"><em>K</em><sub>D</sub> [pM]</th></tr></thead><tbody><tr><td style="border:none;" align="left" rowspan="1" colspan="1">WT</td><td style="border:none;" align="center" rowspan="1" colspan="1">9.4&#x000a0;&#x000b1;&#x000a0;0.3</td><td style="border:none;" align="center" rowspan="1" colspan="1">5.3&#x000a0;&#x000b1;&#x000a0;1.5</td><td style="border:none;" align="center" rowspan="1" colspan="1">183&#x000a0;&#x000b1;&#x000a0;42</td></tr><tr><td style="border:none;" align="left" rowspan="1" colspan="1">F82D</td><td style="border:none;" align="center" rowspan="1" colspan="1">1.4&#x000a0;&#x000b1;&#x000a0;0.1</td><td style="border:none;" align="center" rowspan="1" colspan="1">9.5&#x000a0;&#x000b1;&#x000a0;0.4</td><td style="border:none;" align="center" rowspan="1" colspan="1">14.9&#x000a0;&#x000b1;&#x000a0;2.0</td></tr><tr><td style="border:none;" align="left" rowspan="1" colspan="1">F82D N38C</td><td style="border:none;" align="center" rowspan="1" colspan="1">1.6&#x000a0;&#x000b1;&#x000a0;0.2</td><td style="border:none;" align="center" rowspan="1" colspan="1">13.2&#x000a0;&#x000b1;&#x000a0;0.7</td><td style="border:none;" align="center" rowspan="1" colspan="1">12.3&#x000a0;&#x000b1;&#x000a0;2.0</td></tr><tr><td style="border:none;" align="left" rowspan="1" colspan="1">F82D N38C-Glc</td><td style="border:none;" align="center" rowspan="1" colspan="1">2.9&#x000a0;&#x000b1;&#x000a0;1.6</td><td style="border:none;" align="center" rowspan="1" colspan="1">15.5&#x000a0;&#x000b1;&#x000a0;2.9</td><td style="border:none;" align="center" rowspan="1" colspan="1">18.7&#x000a0;&#x000b1;&#x000a0;1.0</td></tr><tr><td style="border:none;" align="left" rowspan="1" colspan="1">F82D R121C</td><td style="border:none;" align="center" rowspan="1" colspan="1">1.2&#x000a0;&#x000b1;&#x000a0;0.3</td><td style="border:none;" align="center" rowspan="1" colspan="1">8.7&#x000a0;&#x000b1;&#x000a0;0.2</td><td style="border:none;" align="center" rowspan="1" colspan="1">14.1&#x000a0;&#x000b1;&#x000a0;1.6</td></tr><tr><td style="border:none;" align="left" rowspan="1" colspan="1">F82D R121C-SMCC-GlcN</td><td style="border:none;" align="center" rowspan="1" colspan="1">4.2&#x000a0;&#x000b1;&#x000a0;0.6</td><td style="border:none;" align="center" rowspan="1" colspan="1">4.6&#x000a0;&#x000b1;&#x000a0;0.6</td><td style="border:none;" align="center" rowspan="1" colspan="1">93.4&#x000a0;&#x000b1;&#x000a0;26</td></tr><tr><td style="border:none;" align="left" rowspan="1" colspan="1">F82D R121C-4acGlc</td><td style="border:none;" align="center" rowspan="1" colspan="1">2.6&#x000a0;&#x000b1;&#x000a0;0.4</td><td style="border:none;" align="center" rowspan="1" colspan="1">7.3&#x000a0;&#x000b1;&#x000a0;0.8</td><td style="border:none;" align="center" rowspan="1" colspan="1">35.2&#x000a0;&#x000b1;&#x000a0;3.7</td></tr><tr><td style="border:none;" align="left" rowspan="1" colspan="1">F82D R121C-Glc</td><td style="border:none;" align="center" rowspan="1" colspan="1">1.2&#x000a0;&#x000b1;&#x000a0;1.0</td><td style="border:none;" align="center" rowspan="1" colspan="1">7.0&#x000a0;&#x000b1;&#x000a0;6.0</td><td style="border:none;" align="center" rowspan="1" colspan="1">16.6&#x000a0;&#x000b1;&#x000a0;0.4</td></tr><tr><td style="border:none;" align="left" rowspan="1" colspan="1">F82D R121C-Glc*</td><td style="border:none;" align="center" rowspan="1" colspan="1">1.7&#x000a0;&#x000b1;&#x000a0;0.3</td><td style="border:none;" align="center" rowspan="1" colspan="1">1.4&#x000a0;&#x000b1;&#x000a0;0.2</td><td style="border:none;" align="center" rowspan="1" colspan="1">120&#x000a0;&#x000b1;&#x000a0;24</td></tr><tr><td style="border:none;" align="left" rowspan="1" colspan="1">F82D N38C R121C</td><td style="border:none;" align="center" rowspan="1" colspan="1">0.6&#x000a0;&#x000b1;&#x000a0;0.3</td><td style="border:none;" align="center" rowspan="1" colspan="1">7.4&#x000a0;&#x000b1;&#x000a0;0.1</td><td style="border:none;" align="center" rowspan="1" colspan="1">8.4&#x000a0;&#x000b1;&#x000a0;0.5</td></tr><tr><td style="border:none;" align="left" rowspan="1" colspan="1">F82D (Q20N T28N K61N) R121C-Glc*</td><td style="border:none;" align="center" rowspan="1" colspan="1">2.5&#x000a0;&#x000b1;&#x000a0;0.5</td><td style="border:none;" align="center" rowspan="1" colspan="1">2.2&#x000a0;&#x000b1;&#x000a0;1.6</td><td style="border:none;" align="center" rowspan="1" colspan="1">161&#x000a0;&#x000b1;&#x000a0;82</td></tr><tr><td style="border:none;" align="left" rowspan="1" colspan="1">R121D Y124D</td><td style="border:none;" align="center" rowspan="1" colspan="1">9.6&#x000a0;&#x000b1;&#x000a0;1.&#x000a0;5</td><td style="border:none;" align="center" rowspan="1" colspan="1">6.0&#x000a0;&#x000b1;&#x000a0;0.5</td><td style="border:none;" align="center" rowspan="1" colspan="1">163&#x000a0;&#x000b1;&#x000a0;39</td></tr></tbody></table></div><div class="largeobj-link align_right" id="largeobj_idm140686045949136"><a target="object" rel="noopener" href="/pmc/articles/PMC10357448/table/tbl1/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="t1fn1"><sup>a</sup>Association (<em>k</em><sub>on</sub>) and dissociation (<em>k</em><sub>off</sub>) rate
constants, as well as equilibrium binding constants (<em>K</em><sub>D</sub> from <em>K</em><sub>D</sub> = <em>k</em><sub>off</sub>/<em>k</em><sub>on</sub>) from three independent
experiments, are shown (mean and standard deviation). IL-4 variants
marked with asterisk were expressed in the eucaryotic expression system
FreeStyle293 or Expi293 cells and hence, carry N-glycosylation, IL-4
proteins not marked with * were derived from expression in <em>E. coli</em>.</div></div></div><p>The increased affinities of the glycoengineered IL-4
variants are
mainly attributable to slower dissociation rates (<em>k</em><sub>off</sub>) resulting from the mutation F82D (<a href="#tbl1" rid="tbl1" class=" other">Table <a href="#tbl1" rid="tbl1" class=" other">1</a></a>). The latter mutation was initially
found to turn IL-4 into a superagonist due to its increasing affinity
to IL-4R&#x003b1; by a factor of three- to five-fold.<sup><a href="#ref40" rid="ref40" class=" bibr popnode">40</a></sup> It was implemented into our glycoengineered IL-4 antagonists
to compensate for possible affinity decreases that might come with
glycomodifications. For instance, the increase in hydrodynamic radius
due to multiple complex N-glycosylation sites in the IL-4 antagonist
F82D (Q20N T28N K61N) R121C-Glc leads to a slower association resulting
in a lower affinity for IL-4R&#x003b1; (<a href="#tbl1" rid="tbl1" class=" other">Table <a href="#tbl1" rid="tbl1" class=" other">1</a></a>, compare to IL-4 F82D). However, equipped
with the mutation F82D, the IL-4 antagonist IL-4 F82D (Q20N T28N K61N)
R121C-Glc exhibits the same affinity for IL-4R&#x003b1; as wild-type
IL-4 and can thus effectively compete off endogenous IL-4 from the
IL-4 receptor. For disulfide-linked glucose- and glucose tetraacetate-modified
IL-4 F82D R121C, the SPR analysis revealed affinities of 17 and 35
pM, respectively. The IL-4 conjugate F82D R121C coupled to SMCC-glucosamine
exhibited a lower affinity (<em>K</em><sub>D</sub> about 90
pM). This lower affinity (when compared to disulfide-linked glycoconjugates)
points toward steric hindrance of IL-4R&#x003b1; binding due to the
relatively large size of the bifunctional crosslinker, which is absent
in IL-4 glycoconjugates in which the carbohydrate is directly coupled
via a disulfide bond (see <a href="/pmc/articles/PMC10357448/figure/fig4/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig4" rid-ob="ob-fig4" co-legend-rid="lgnd_fig4"><span>Figure <a href="/pmc/articles/PMC10357448/figure/fig4/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig4" rid-ob="ob-fig4" co-legend-rid="lgnd_fig4"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure4</span></span><span>4</span></a></span></a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="fig4" co-legend-rid="lgnd_fig4"><a href="/pmc/articles/PMC10357448/figure/fig4/" target="figure" rid-figpopup="fig4" rid-ob="ob-fig4"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140686052578688"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10357448_ao3c00726_0005.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is ao3c00726_0005.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC10357448/bin/ao3c00726_0005.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140686052578688"><a target="object" rel="noopener" href="/pmc/articles/PMC10357448/figure/fig4/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_fig4"><div><a class="figpopup" href="/pmc/articles/PMC10357448/figure/fig4/" target="figure" rid-figpopup="fig4" rid-ob="ob-fig4">Figure 4</a></div><!--caption a7--><div class="caption"><p>Steric hindrance introduced by site-specific glycoconjugation.
(A) Binding sites for the IL-4 receptors IL-4R&#x003b1; (in light orange)
and IL-13R&#x003b1;1 (in light cyan/gray) were deduced from the crystal
structure of the ternary IL-4 type II receptor complex (PDB entry <a href="https://www.rcsb.org/structure/3BPN" data-ga-action="click_feat_suppl" ref="reftype=extlink-pdb&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CPDB" target="_blank">3BPN</a>(<a href="#ref47" rid="ref47" class=" bibr popnode">47</a>)) and are marked in orange (IL-4R&#x003b1; epitope) and cyan
(&#x003b3;c/IL-13R&#x003b1;1 binding site, only the epitope utilized by
both receptors is color-coded), respectively. (B) Conjugation of an
amine-containing carbohydrate via the bifunctional crosslinker SMCC
to Cys121 results in a rather long chain that can possibly extend
to the binding site for IL-4R&#x003b1;, resulting in decreased binding
affinity for IL-4R&#x003b1;, thereby limiting the antagonistic efficacy
of such glycoengineered IL-4 variants. (C) Direct coupling of thiol-containing
carbohydrates (a glucose moiety is shown) to Cys121 via a disulfide
bond limits the steric hindrance to &#x003b3;c/IL-13R&#x003b1;1 binding.</p></div></div></div><p>Biological activities and IL-4 inhibitory capacities
of IL-4 F82D
R121C glycoconjugates were assessed using two cell-based experiments.
HEK-Blue IL-4/IL-13 cells (Invivogen) carry a secreted alkaline phosphatase
(SEAP) reporter gene downstream of an IL-4/IL-13 responsive promoter.
As HEK-Blue cells only express IL-4R&#x003b1; and IL-13R&#x003b1;1, they
present a reporter system specific for IL-4 receptor type II signaling.
IL-4/IL-13 biological activity can also be quantified using the human
erythroleukemic cell line TF-1, which proliferates in response to
IL-4 and IL-13.<sup><a href="#ref48" rid="ref48" class=" bibr popnode">48</a></sup> TF-1 cells express all
three receptors IL-4R&#x003b1;, &#x003b3;c, and IL-13R&#x003b1;1 (expression
was confirmed by qRT-PCR; <a href="https://pubs.acs.org/doi/suppl/10.1021/acsomega.3c00726/suppl_file/ao3c00726_si_001.pdf" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Figure S8</a>) and
can be used to quantify IL-4 receptor type I- and type II-dependent
signaling. Both cell lines demonstrated high sensitivity for IL-4
with half-maximal effective concentrations (EC50) of 3.6 &#x000b1; 1.0
pM for wild-type IL-4 (IL-4 WT) in HEK-Blue cells and 6.7 &#x000b1; 1.5
pM for wild-type IL-4 in TF-1 cells consistent with the published
data.<sup><a href="#ref28" rid="ref28" class=" bibr popnode">28</a>,<a href="#ref34" rid="ref34" class=" bibr popnode">34</a></sup></p><p>At a concentration of 50 pM, none
of the IL-4 F82D R121C glycoconjugates,
irrespective of whether they were conjugated to SMCC-glucosamine or
disulfide-linked to glucose or glucose tetraacetate, exhibited any
biological activity (&#x0003c;1%) in HEK-Blue or TF-1 cells, similar to
the benchmark Pitrakinra (IL-4 R121D Y124D) (<a href="/pmc/articles/PMC10357448/figure/fig5/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig5" rid-ob="ob-fig5" co-legend-rid="lgnd_fig5"><span>Figure <a href="/pmc/articles/PMC10357448/figure/fig5/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig5" rid-ob="ob-fig5" co-legend-rid="lgnd_fig5"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure5</span></span><span>5</span></a></span></a>). This is noteworthy, as for Pitrakinra
exchange of Arg121 as well as Tyr124 against aspartate was necessary
to shut off signaling through both type I and type II IL-4 receptors.
Mutation of only Arg121 in IL-4 R121E blocked signaling via the IL-4,
type II receptor, but IL-4 R121E could still efficiently stimulate
TF-1 cell proliferation (maximal proliferation was 73 &#x000b1; 12% compared
with wild-type IL-4) consistent with IL-4 R121E being reported as
a IL-4 type II receptor-specific antagonist.<sup><a href="#ref49" rid="ref49" class=" bibr popnode">49</a></sup></p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="fig5" co-legend-rid="lgnd_fig5"><a href="/pmc/articles/PMC10357448/figure/fig5/" target="figure" rid-figpopup="fig5" rid-ob="ob-fig5"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140686049657808"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10357448_ao3c00726_0006.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is ao3c00726_0006.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC10357448/bin/ao3c00726_0006.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140686049657808"><a target="object" rel="noopener" href="/pmc/articles/PMC10357448/figure/fig5/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_fig5"><div><a class="figpopup" href="/pmc/articles/PMC10357448/figure/fig5/" target="figure" rid-figpopup="fig5" rid-ob="ob-fig5">Figure 5</a></div><!--caption a7--><div class="caption"><p>Cell
assay analysis of IL-4 F82D R121C glycoconjugates. (a) Biological
activity of IL-4 variants and glycoconjugates thereof in HEK-Blue
and TF-1 cells. Cells were stimulated with 50 pM of each variant and
signal intensity was normalized to wild-type IL-4. Data are from three
independent experiments. 1: WT; 2: F82D N38C-Glc; 3: F82D R121C-SMCC-GlcN;
4: F82D R121C-Glc; 5: F82D R121C-4acGlc; 6: F82D R121C-Glc (HEK293);
7: R121D Y124D; 8: F82D R121E. (b) Dose-response curves of IL-4 F82D
R121C glycoconjugates in TF-1 cells. Cells were stimulated with a
log&#x0202f;2 concentration series of the indicated variants in the
presence of 50 pM wild-type IL-4. Signal intensity was normalized
to stimulation by 50 pM wild-type IL-4 alone. Data are from three
independent experiments.</p></div></div></div><p>This shows that binding of &#x003b3;c and IL-13R&#x003b1;1
to IL-4
can be efficiently blocked by steric hindrance through a single-site
conjugation at position 121 using a monosaccharide, while exchange
with other amino acids requires simultaneous mutation at positions
121 and 124 to obtain a full IL-4 antagonist. Hence, steric hindrance
as the working principle to generate an IL-4 full antagonist is superior
to the electrostatic mismatch strategy used in the design of Pitrakinra.<sup><a href="#ref32" rid="ref32" class=" bibr popnode">32</a></sup> To test that chemical glycoconjugation during
refolding occurs site-specifically to the engineered cysteine residue,
the glucose-conjugated IL-4 variants F82D and N38C served as a control.
As position 38 presents the natural N-glycosylation site located far
outside any receptor epitope, modification with thio-glycans should
thus not interfere with IL-4 activity. This conjugate indeed exhibited
biological activities identical to wild-type IL-4 (<a href="/pmc/articles/PMC10357448/figure/fig5/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig5" rid-ob="ob-fig5" co-legend-rid="lgnd_fig5"><span>Figure <a href="/pmc/articles/PMC10357448/figure/fig5/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig5" rid-ob="ob-fig5" co-legend-rid="lgnd_fig5"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure5</span></span><span>5</span></a></span></a>), thereby confirming thio-saccharide
coupling during refolding occurred specifically on the engineered
cysteine and did not alter the native disulfide bonding pattern.</p><p class="p">To evaluate antagonistic efficacy of IL-4 F82D R121C glycoconjugates,
we determined the half-maximal inhibitory concentration (IC50) by
evaluating the competition of IL-4-induced TF-1 cell proliferation
(<a href="/pmc/articles/PMC10357448/figure/fig5/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig5" rid-ob="ob-fig5" co-legend-rid="lgnd_fig5"><span>Figure <a href="/pmc/articles/PMC10357448/figure/fig5/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig5" rid-ob="ob-fig5" co-legend-rid="lgnd_fig5"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure5</span></span><span>5</span></a></span></a>), as well
as dose-dependent inhibition of IL-4-induced expression of secreted
alkaline phosphatase (SEAP) in HEK-Blue cells. For quantitative analysis,
the inhibitory constant (<em>K</em><sub>i</sub>) was calculated
using the Cheng&#x02013;Prusoff equation (<em>K</em><sub>i</sub> = IC<sub>50</sub>/(1 + [IL-4]/EC<sub>50</sub>)).<sup><a href="#ref50" rid="ref50" class=" bibr popnode">50</a></sup> The inhibitory constant presents a measure of the receptor
affinity of an antagonist, i.e., the engineered IL-4 F82D and R121C
glycoconjugates for IL-4R&#x003b1;. The glucose and glucose tetraacetate
IL-4 conjugates showed a <em>K</em><sub>i</sub> of about 20
pM in TF-1 and HEK-Blue cells (determined only for the glucose conjugate),
indicating that these novel IL-4 antagonists are 5 times more effective
than Pitrakinra (<em>K</em><sub>i</sub> &#x02248; 100 pM) (<a href="#tbl2" rid="tbl2" class=" other">Table <a href="#tbl2" rid="tbl2" class=" other">2</a></a>). With a <em>K</em><sub>i</sub> of about 50 pM, IL-4-SMCC-GlcN was a slightly
less potent antagonist, consistent with its lower IL-4R&#x003b1; affinity.
These data demonstrate that the glycoengineered IL-4 F82D R121C conjugates
block IL-4 type I and type II receptors and present highly effective
IL-4 antagonists (<a href="/pmc/articles/PMC10357448/figure/fig5/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig5" rid-ob="ob-fig5" co-legend-rid="lgnd_fig5"><span>Figure <a href="/pmc/articles/PMC10357448/figure/fig5/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig5" rid-ob="ob-fig5" co-legend-rid="lgnd_fig5"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure5</span></span><span>5</span></a></span></a> and <a href="#tbl2" rid="tbl2" class=" other">Table <a href="#tbl2" rid="tbl2" class=" other">2</a></a>).</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap anchored whole_rhythm" id="tbl2"><h3>Table 2</h3><!--caption a7--><div class="caption"><!--caption a8--><strong>Inhibition of IL-4 Signaling by IL-4
F82D R121C Glycoconjugates<sup>a</sup></strong></div><div class="xtable"><table frame="hsides" rules="groups" border="0" class="rendered small default_table"><thead><tr><th style="border:none;" align="center" rowspan="1" colspan="1">&#x000a0;</th><th colspan="2" align="center" rowspan="1">inhibitory
constant (<em>K</em><sub>i</sub>) [pM]<hr /></th></tr><tr><th style="border:none;" align="center" rowspan="1" colspan="1">IL-4 variant</th><th style="border:none;" align="center" rowspan="1" colspan="1">TF-1</th><th style="border:none;" align="center" rowspan="1" colspan="1">HEK-Blue</th></tr></thead><tbody><tr><td style="border:none;" align="left" rowspan="1" colspan="1">F82D R121C-SMCC-GlcN</td><td style="border:none;" align="center" rowspan="1" colspan="1">51.2&#x000a0;&#x000b1;&#x000a0;10.4</td><td style="border:none;" align="left" rowspan="1" colspan="1">ND</td></tr><tr><td style="border:none;" align="left" rowspan="1" colspan="1">F82D R121C-Glc</td><td style="border:none;" align="center" rowspan="1" colspan="1">17.4&#x000a0;&#x000b1;&#x000a0;6.4</td><td style="border:none;" align="left" rowspan="1" colspan="1">13.1&#x000a0;&#x000b1;&#x000a0;4.1</td></tr><tr><td style="border:none;" align="left" rowspan="1" colspan="1">F82D R121C-4acGlc</td><td style="border:none;" align="center" rowspan="1" colspan="1">14.6&#x000a0;&#x000b1;&#x000a0;6.3</td><td style="border:none;" align="left" rowspan="1" colspan="1">ND</td></tr><tr><td style="border:none;" align="left" rowspan="1" colspan="1">R121D Y124D (Pitrakinra)</td><td style="border:none;" align="center" rowspan="1" colspan="1">98.3&#x000a0;&#x000b1;&#x000a0;21.3</td><td style="border:none;" align="left" rowspan="1" colspan="1">82.4&#x000a0;&#x000b1;&#x000a0;20.7</td></tr></tbody></table></div><div class="largeobj-link align_right" id="largeobj_idm140686094330080"><a target="object" rel="noopener" href="/pmc/articles/PMC10357448/table/tbl2/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="t2fn1"><sup>a</sup>Inhibition constants <em>K</em><sub>i</sub> were calculated employing the Cheng&#x02013;Prusoff equation
using IC<sub>50</sub> values of different IL-4 F82D R121C glycoconjugates
and the EC<sub>50</sub> obtained for wild-type IL-4 (TF-1: 6.7 &#x000b1;
1.5 pM; HEK-Blue: 3.6 &#x000b1; 1.0 pM). Data were derived from three
independent experiments using TF-1 cell proliferation and HEK-Blue
SEAP assays. ND = not determined.</div></div></div></div><div id="sec2.6" class="sec"><h3 id="sec2.6title">Multi-Glycosylated Variants for Enhanced Protein Stability</h3><p class="p p-first">Pitrakinra exhibited a short serum half-life, estimated to be about
3 h, which severely limited its therapeutic activity <em>in vivo</em>.<sup><a href="#ref30" rid="ref30" class=" bibr popnode">30</a></sup> The small size of 15 kDa and its lack
of glycosylation were likely the key determinants, which facilitated
fast systemic clearance, <em>e.g.</em>, via renal filtration
and protein degradation. Accordingly, increasing Pitrakinra&#x02032;s
size through conjugation of a 40 kDa PEG polymer improved serum half-life
to about 5 days, but also decreased its efficacy as IL-4 antagonist,
as the long PEG moiety critically affected IL-4R&#x003b1; binding.<sup><a href="#ref31" rid="ref31" class=" bibr popnode">31</a></sup> As for PEGylated proteins, glycoproteins with
complex mammalian-like glycan structures exhibit an increased circulatory
lifetime, and are more resistant to proteolysis, and usually have
a higher physicochemical stability compared with their non-glycosylated
forms.<sup><a href="#ref37" rid="ref37" class=" bibr popnode">37</a></sup> Since automated chemical synthesis
of complex glycans is not yet realized, only a few mostly simpler
glycans at a rather high cost are available for chemical glycoengineering.
We thus tested whether a multi-glycosylated IL-4 variant containing
complex N-glycans can be produced using an eukaryotic expression system
and combined with chemical glycosylation of Cys121 to yield an IL-4
antagonist with enhanced pharmacokinetic properties. Several N-glycosylation
motifs were introduced in IL-4 F82D by altering the amino acid sequence
to N-X-S/T with X not being proline. All sites were chosen to require
minimal mutations, ideally a single amino acid exchange, to yield
an N-X-S/T degron. Furthermore, only positions outside of secondary
structure elements were considered to avoid that these novel sites
might not be recognized by glycosyltransferases in the ER. Third,
N-glycosylation motifs were introduced at sites that will not interfere
with IL-4&#x02013;IL-4R&#x003b1; binding, which would impair antagonist
efficacy by lowering the binding affinity to the IL-4 high-affinity
receptor IL-4R&#x003b1;. Obeying these requirements three IL-4 single
amino acid variants, i.e., Q20N, T28N, and K61N, were produced in
HEK293 cells and SDS-PAGE analysis indicated that all three N-glycosylation
sites were processed (<a href="/pmc/articles/PMC10357448/figure/fig6/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig6" rid-ob="ob-fig6" co-legend-rid="lgnd_fig6"><span>Figure <a href="/pmc/articles/PMC10357448/figure/fig6/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig6" rid-ob="ob-fig6" co-legend-rid="lgnd_fig6"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure6</span></span><span>6</span></a></span></a>). To confirm that the increase in molecular mass is due to
N-glycosylation, the glycoengineered IL-4 variants were subjected
to enzymatic hydrolysis employing endoglycosidase PNGase F, which
hydrolyzes N-linked oligosaccharides from glycoproteins (<a href="https://pubs.acs.org/doi/suppl/10.1021/acsomega.3c00726/suppl_file/ao3c00726_si_001.pdf" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Figure S9</a>). From those, we designed an IL-4 multivariant
comprising three additional N-glycosylation sites, combining mutations
Q20N, T28N, and K61N. SDS-PAGE analysis of IL-4 F82D Q20N T28N K61N
revealed an apparent molecular weight of 25&#x02013;35 kDa (<a href="/pmc/articles/PMC10357448/figure/fig6/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig6" rid-ob="ob-fig6" co-legend-rid="lgnd_fig6"><span>Figure <a href="/pmc/articles/PMC10357448/figure/fig6/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig6" rid-ob="ob-fig6" co-legend-rid="lgnd_fig6"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure6</span></span><span>6</span></a></span></a>), which is about
twice the molecular weight of <em>E. coli</em>-derived wild-type IL-4/Pitrakinra.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="fig6" co-legend-rid="lgnd_fig6"><a href="/pmc/articles/PMC10357448/figure/fig6/" target="figure" rid-figpopup="fig6" rid-ob="ob-fig6"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140686047914320"><img loading="lazy" class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is ao3c00726_0007.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is ao3c00726_0007.jpg" src="/pmc/articles/PMC10357448/bin/ao3c00726_0007.jpg" /></div><div class="largeobj-link align_right" id="largeobj_idm140686047914320"><a target="object" rel="noopener" href="/pmc/articles/PMC10357448/figure/fig6/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_fig6"><div><a class="figpopup" href="/pmc/articles/PMC10357448/figure/fig6/" target="figure" rid-figpopup="fig6" rid-ob="ob-fig6">Figure 6</a></div><!--caption a7--><div class="caption"><p>SDS-PAGE analysis of HEK293 cell-derived
IL-4 multi-glycosylated
variants. An SDS-PAGE analysis was performed under non-reducing conditions
and the gel was stained first using acid&#x02013;Schiff staining (right
panel) to highlight glycosylations before Coomassie blue staining
was used to detect the protein. 1, 8: molecular weight standard; 2:
F82D N38Q; 3: WT; 4: F82D Q20N; 5: F82D T28N; 6: F82D K61N; 7: F82D
Q20N T28N K61N.</p></div></div></div><p class="p p-last">Chemical glycosylation of HEK293 cell-derived IL-4
variants harboring
an engineered cysteine required the refolding procedure for modification.
Mass spectrometry of such HEK293 cell-derived IL-4 revealed that the
unpaired cysteine was conjugated to another cysteine stemming from
the cell culture media, which could not be removed by enzymatic deglutathionylation
as glutaredoxins are specific for glutathione. Purified IL-4 F82D
(Q20N T28N K61N) R121C was therefore first denatured and its cystine
residues were reduced using 1 mM DTT. Oxidative refolding was then
performed as described above employing rapid dilution with the protein
concentration adjusted to 1 mg/mL and in the presence of 1 mM thiol-glucose.
Incubation proceeded for 72 h, after which modified IL-4 could be
recovered with 30% yield. Mass spectrometry analysis not only confirmed
the disulfide formation between Cys121 and thiol-glucose, but also
showed that all native disulfide bonds in IL-4 were formed. After
purification, only IL-4 protein containing a native disulfide pattern
was obtained. SPR analysis was performed to test whether the additional
N-glycosylation affects IL-4R&#x003b1; binding (<a href="https://pubs.acs.org/doi/suppl/10.1021/acsomega.3c00726/suppl_file/ao3c00726_si_001.pdf" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Figure S7</a>). Chemically glycosylated HEK293 cell-derived IL-4
F82D R121C containing a single N-glycan at position 38 exhibited an
affinity of 120&#x000b1;24 pM for IL-4R&#x003b1; and served as reference.
IL-4 variant F82D (Q20N T28N K61N) R121C with N-glycans at positions
20, 28, 38 (native site), and 61 and with Cys121 coupled to thio-glucose
bound IL-4R&#x003b1; with an affinity of 161&#x000b1;82 pM. The 13 times
lower affinity compared to bacteria-derived IL-4 F82D R121C-Glc (<em>K</em><sub>D</sub> 16.6 &#x000b1; 0.4 pM) is likely due to increased
molecular size from the N-glycans, which slows down the association.
However, due to the affinity-enhancing mutation F82D,<sup><a href="#ref40" rid="ref40" class=" bibr popnode">40</a></sup> binding affinities of this multi-glycosylated IL-4 variant
are not weaker than wild-type IL-4 (<em>K</em><sub>D</sub>: 183&#x000b1;42 pM) or Pitrakinra (<em>K</em><sub>D</sub>:
163&#x000b1;39 pM) (see also <a href="#tbl1" rid="tbl1" class=" other">Table <a href="#tbl1" rid="tbl1" class=" other">1</a></a>). Antagonist efficacy was determined from the inhibition
of IL-4-mediated TF-1 cell proliferation showing that HEK293 cell-derived
IL-4 F82D (Q20N T28N K61N) R121C-Glc exhibits a <em>K</em><sub>i</sub> value of 184&#x000b1;55 pM (<a href="https://pubs.acs.org/doi/suppl/10.1021/acsomega.3c00726/suppl_file/ao3c00726_si_001.pdf" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Figure S10</a>) correlating with its <em>K</em><sub>D</sub> value
determined by SPR experiments.</p></div><div id="sec2.7" class="sec sec-last"><h3 id="sec2.7title">IL-4 Variants with Additional N-Glycosylation Have Enhanced
Proteolytic Stability</h3><p class="p p-first">Several studies have reported that
glycosylation can confer proteolytic stability by masking proteolytic
cleavage sites in proteins.<sup><a href="#ref51" rid="ref51" class=" bibr popnode">51</a>,<a href="#ref52" rid="ref52" class=" bibr popnode">52</a></sup> We analyzed whether
our multi-glycosylated IL-4 variants also show increased proteolytic
stability <em>in vitro</em>. IL-4 proteins from different
expression systems differing in the glycan structure and content were
incubated with trypsin as a model protease. Long-term treatment of
bacteria-derived IL-4 resulted in complete hydrolysis and thus served
as a benchmark. Proteolysis was monitored by SDS-PAGE analysis of
samples taken at different incubation times and quantified from Coomassie
staining intensity of the residual non-degraded IL-4 protein using
the software ImageLab (Bio-Rad). The &#x0201c;proteolytic half-life&#x0201d;
of each IL-4 protein was then calculated by one-phase decay using
sPrism software (<a href="#tbl3" rid="tbl3" class=" other">Table <a href="#tbl3" rid="tbl3" class=" other">3</a></a>; see also <a href="https://pubs.acs.org/doi/suppl/10.1021/acsomega.3c00726/suppl_file/ao3c00726_si_001.pdf" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Figure S11</a>). Mutations F82D
and R121C did not affect proteolytic sensitivity compared to wild-type
IL-4 (see also <a href="https://pubs.acs.org/doi/suppl/10.1021/acsomega.3c00726/suppl_file/ao3c00726_si_001.pdf" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Table S4</a>). Non-glycosylated <em>E. coli</em>-derived proteins such as IL-4 F82D were highly
susceptible to trypsin proteolysis and under these conditions exhibited
rather short proteolytic half-lives of about 1 h. The HEK293 cell-derived
IL-4 variant N38Q lacking all N-glycosylation was also degraded rather
rapidly (<em>t</em><sub>1/2</sub> 2.4 h). Interleukin-4 F82D
obtained from HEK293 cells, which carries a single complex N-glycan,
exhibited a proteolytic half-life of about 4.5&#x02013;5 h, indicating
that a single glycan moiety already improved proteolytic stability
(<a href="#tbl3" rid="tbl3" class=" other">Table <a href="#tbl3" rid="tbl3" class=" other">3</a></a>).</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap anchored whole_rhythm" id="tbl3"><h3>Table 3</h3><!--caption a7--><div class="caption"><!--caption a8--><strong>Proteolytic Stability of Differently
Glycosylated IL-4 Variants<sup>a</sup></strong></div><div class="xtable"><table frame="hsides" rules="groups" border="0" class="rendered small default_table"><thead><tr><th style="border:none;" align="center" rowspan="1" colspan="1">IL-4 variant</th><th style="border:none;" align="center" rowspan="1" colspan="1">amount of N-glycans</th><th style="border:none;" align="center" rowspan="1" colspan="1">half-life [h]</th></tr></thead><tbody><tr><td style="border:none;" align="left" rowspan="1" colspan="1">F82D (<em>E. coli</em>)</td><td style="border:none;" align="center" rowspan="1" colspan="1">0</td><td style="border:none;" align="center" rowspan="1" colspan="1">0.9&#x000a0;&#x000b1;&#x000a0;0.01</td></tr><tr><td style="border:none;" align="left" rowspan="1" colspan="1">F82D N38Q (HEK293)</td><td style="border:none;" align="center" rowspan="1" colspan="1">0</td><td style="border:none;" align="center" rowspan="1" colspan="1">2.4&#x000a0;&#x000b1;&#x000a0;0.1</td></tr><tr><td style="border:none;" align="left" rowspan="1" colspan="1">F82D (HEK293)</td><td style="border:none;" align="center" rowspan="1" colspan="1">1</td><td style="border:none;" align="center" rowspan="1" colspan="1">4.7&#x000a0;&#x000b1;&#x000a0;1.7</td></tr><tr><td style="border:none;" align="left" rowspan="1" colspan="1">F82D Q20N (HEK293)</td><td style="border:none;" align="center" rowspan="1" colspan="1">2</td><td style="border:none;" align="center" rowspan="1" colspan="1">10.5&#x000a0;&#x000b1;&#x000a0;0.6</td></tr><tr><td style="border:none;" align="left" rowspan="1" colspan="1">F82D Q20N T28N-K61N (HEK293)</td><td style="border:none;" align="center" rowspan="1" colspan="1">4</td><td style="border:none;" align="center" rowspan="1" colspan="1">25.4&#x000a0;&#x000b1;&#x000a0;2.8</td></tr><tr><td style="border:none;" align="left" rowspan="1" colspan="1">WT (<em>P. pastoris</em>)</td><td style="border:none;" align="center" rowspan="1" colspan="1">1</td><td style="border:none;" align="center" rowspan="1" colspan="1">2.6&#x000a0;&#x000b1;&#x000a0;0.2</td></tr><tr><td style="border:none;" align="left" rowspan="1" colspan="1">WT (HEK293)</td><td style="border:none;" align="center" rowspan="1" colspan="1">1</td><td style="border:none;" align="center" rowspan="1" colspan="1">4.9&#x000a0;&#x000b1;&#x000a0;0.7</td></tr><tr><td style="border:none;" align="left" rowspan="1" colspan="1">WT (<em>E. coli</em>)</td><td style="border:none;" align="center" rowspan="1" colspan="1">0</td><td style="border:none;" align="center" rowspan="1" colspan="1">1.7&#x000a0;&#x000b1;&#x000a0;0.1</td></tr></tbody></table></div><div class="largeobj-link align_right" id="largeobj_idm140686095487760"><a target="object" rel="noopener" href="/pmc/articles/PMC10357448/table/tbl3/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="t3fn1"><sup>a</sup>Resistance to <em>in vitro</em> proteolysis was determined for IL-4 proteins with different level
of glycosylation. Proteins were hydrolyzed with trypsin and degradation
at different times was monitored using SDS-PAGE analysis. The level
of the non-degraded IL-4 protein was determined by densiometric analysis
of Coomassie-stained gels and fitted by an equation of exponential
decay to yield values of proteolytic half-life. Mean and standard
deviation from two independent experiments are shown.</div></div></div><p class="p p-last">Conformingly, variants harboring two (Q20N and the
natural N-glycosylation
site at Asn38) or four N-glycans (Q20N T28N-K61N and Asn38) showed
strongly enhanced stability against degradation by trypsin (<em>t</em><sub>1/2</sub> 10.5 and 25 h, respectively). This clearly
indicates that the proteolytic stability of IL-4 can be increased
considerably <em>in vitro</em> by additional N-glycans using
HEK293 cells as the expression system. Importantly, the size of the
N-glycan moiety does not seem to be the determining factor of proteolytic
stability, as IL-4 produced in the yeast <em>Pichia pastoris</em>, which carried a single large N-glycan of about 20 kDa size (determined
by SDS-PAGE, see <a href="https://pubs.acs.org/doi/suppl/10.1021/acsomega.3c00726/suppl_file/ao3c00726_si_001.pdf" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Figure S12</a>), had a proteolytic
half-life of only 2.6 h. Hence, albeit the yeast-derived IL-4 protein
contained an N-glycan moiety about 8&#x02013;10 times the size of the
N-glycan moiety attached by mammalian cells (average N-glycan size
is about 2&#x02013;3 kDa), HEK293 cell-derived IL-4 carrying a single
N-glycan exhibited similar proteolytic stability. This discrepancy
might possibly be due to the difference in the glycan architecture
and composition, as mammalian cells produce N-glycans of hybrid or
complex type usually containing terminal negatively charged sialic
acid residues, whereas yeast produces proteins attached to poly-mannose
glycans not shielded by sialic acid end groups.<sup><a href="#ref53" rid="ref53" class=" bibr popnode">53</a></sup></p></div></div><div id="sec3" class="tsec sec"><h2 class="head no_bottom_margin" id="sec3title">Discussion</h2><p class="p p-first">In this study, we established different
reaction schemes for chemical
glycoengineering, which allowed site-specific conjugation of amine-
or thiol-functionalized carbohydrate molecules to IL-4 harboring an
unpaired cysteine. In this novel setup, a carbohydrate molecule was
chemically introduced at an engineered site to block receptor binding
ultimately conferring an inhibitory effect and converting the protein
into an antagonist. Hence, these IL-4 F82D R121C conjugates were highly
effective IL-4 antagonists <em>in vitro</em>, more potent
than the benchmark Pitrakinra. By developing a procedure allowing
chemical glycosylation during refolding of the (insolubly expressed)
IL-4 protein, we obtained a fast strategy that neither requires enzymatic
deglutathionylation nor thiol-activation for efficient coupling. Compared
to other strategies, this scheme allows for time-efficient synthesis
of chemically glycosylated IL-4 in high yield with almost 100% conjugation
efficiency, thereby decreasing the number of purification steps. Furthermore,
this strategy allows the coupling of the glycan moiety directly with
the protein without the need for a (bifunctional) linker. As the latter
has a certain minimal length due to the steric requirement of the
chemical groups needed for conjugation a linker-mediated conjugation
approach will inevitably display the glycan moiety in a hapten-like
manner. This, however, might lead to recognition of this unusual chemical
structure by the immune system and trigger unwanted immune responses
against the therapeutic. With minor adjustments, the direct chemical
glycosylation strategy could also be applied to HEK293 cell-derived
(multi)glycosylated IL-4 F82D R121C variants containing up to four
engineered N-glycosylation sites. This provides a combination of chemical
and biosynthetic glycoengineering in which antagonist functionality
is implemented through chemical glycosylation and additional N-glycosylation
adds complex N-glycan moieties to positively modulate pharmacokinetic
properties such as <em>in vivo</em> half-life and immunogenicity.</p><p><em>In vitro</em> proteolysis assays revealed that in comparison
to non-glycosylated proteins such multi-glycosylated IL-4 antagonists
not only maintain their very high inhibition efficacy but also acquire
a &#x02265;30-fold increased stability against proteolytic degradation
through trypsin. While IL-4 is not a physiological substrate of trypsin <em>in vivo</em>, similar biophysical and protein chemical parameters
that confer resistance to trypsin degradation will also increase stability
against proteases, <em>e.g.</em>, matrix metalloproteinases
(MMPs), which might be physiologically more relevant for IL-4 degradation.
These data suggest that such glycoengineered IL-4 inhibitors/antagonists
likely exhibit improved pharmacokinetics properties <em>in vivo</em> compared to the original drug Pitrakinra and therefore present alternatives
to classical IL-4 inhibitors such as the neutralizing anti-IL-4R&#x003b1;
antibody Dupilumab.</p><p class="p p-last">From a long-term perspective, the conjugation
of complex human-like
N-glycan structures to proteins purely carried out by chemical procedures
will be the ultimate goal making the expression in eukaryotic expression
hosts dispensable and allowing the production of chemically highly
defined protein glycoconjugates. Obtaining a defined homogeneous conjugate
would also allow the use of tailored glycan structures that can be
used to modulate targeting of the pharmaceutical compound to desired
target sites, facilitate the prediction, or modulate metabolic degradation,
thereby enabling fine-tuning of pharmacokinetic properties. In a proof-of-principle
experiment, the refolding strategy presented here readily allowed
multi-site glycoconjugation of IL-4 cysteine variants. Given that
an automated synthesis of complex glycans might be realized in the
near future, this chemical glycoengineering will facilitate the preparation
of pharmacologically optimized IL-4 antagonists but might also be
applied for the production of other glycoproteins.</p></div><div id="sec4" class="tsec sec"><h2 class="head no_bottom_margin" id="sec4title">Experimental Procedures</h2><div id="sec4.1" class="sec sec-first"><h3 id="sec4.1title">Production of IL-4 in <em>E. coli</em> for Site-Directed Chemical Glycosylation</h3><p class="p p-first-last">The cDNA encoding
IL-4 variants were synthesized by two-step PCR mutagenesis (oligonucleotide
sequences see <a href="https://pubs.acs.org/doi/suppl/10.1021/acsomega.3c00726/suppl_file/ao3c00726_si_001.pdf" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Table S3</a>). Expression, purification,
and enzymatic deglutathionylation of <em>E. coli</em>-derived IL-4 cysteine variants were performed as described.<sup><a href="#ref33" rid="ref33" class=" bibr popnode">33</a></sup></p></div><div id="sec4.2" class="sec"><h3 id="sec4.2title">Coupling of IL-4 Cysteine Variants to Amine-Containing Carbohydrates
via the Bifunctional Crosslinker SMCC</h3><p class="p p-first-last">The crosslinker SMCC
(succinimidyl-4-(<em>N</em>-maleimido-methyl)-cyclohexane-1-carboxylate)
was dissolved at 100 mM in acetonitrile. A 400 mM glucosamine solution
was prepared in 100 mM sodium phosphate and 4 mM EDTA, pH 8.0. In
the first approach, these two solutions were mixed in volumetric 1:1
ratio, which resulted in a reaction mixture with a pH of 6.5. This
mixture was then incubated at 21 &#x000b0;C for 2 h to allow for coupling
of the amino group of glucosamine to the carboxylate group of SMCC.
The SMCC-glucosamine conjugate was purified by reversed-phase HPLC
(RP-HPLC) using a C18-column (&#x003bc;RPC C2/C18 ST 4.6/100, GE Healthcare)
employing a gradient of 0.1% TFA/H<sub>2</sub>O to 100% acetonitrile.
The coupling product was eluted at 55&#x02013;60% acetonitrile. Conjugate-containing
fractions were pooled and freeze-dried. In a revised setup glucosamine-HCl
was dissolved in 200 mM sodium phosphate, 8 mM EDTA pH 8.0, and the
pH of the glucosamine solution was adjusted to pH 7.2 by adding 1
M sodium hydroxide dropwise. This glucosamine-phosphate solution was
then reacted with 100 mM SMCC solution in acetonitrile or alternatively
with SMCC dissolved in dimethylsulfoxide. The alternative setups were
reacted and purified as described above. Deglutathionylated IL-4 containing
an unpaired cysteine was dissolved in 100 mM sodium phosphate (pH
6.5), glucosamine-SMCC conjugate was dissolved in acetonitrile at
5 mM concentration and both solutions were mixed in a 1:100 molar
ratio (protein:gluco-SMCC conjugate). After incubating at 21 &#x000b0;C
for 2 h, the IL-4 SMCC glycoconjugate was purified by RP-HPLC employing
a C4 column (Jupiter C4, 10 &#x003bc;m, 250 mm &#x000d7; 10 mm, Phenomenex,
Germany) and a gradient of 0.1% TFA in H<sub>2</sub>O to 100% acetonitrile
in five column volumes.</p></div><div id="sec4.3" class="sec"><h3 id="sec4.3title">Coupling of IL-4 Cysteine Variants to Thiol-Carbohydrates Using
Phenylselenyl Bromide Activation</h3><p class="p p-first-last">Deglutathionylated IL-4
protein containing an unpaired cysteine was dissolved in 10 mM CHES,
70 mM MES, and 2 mM CaCl<sub>2</sub> (pH 9.5) to a concentration of
66 &#x003bc;M. Phenylselenyl bromide was dissolved at 100 mM in acetonitrile.
The reaction was started by mixing the phenylselenyl bromide and protein
solutions in a 40:1 molar ratio. The mixture was incubated at 21 &#x000b0;C
for 1 h. Non-reacted phenylselenyl bromide and by-products were removed
by size exclusion using a PD10 column (GE Healthcare). Protein-containing
fractions were pooled and stored at &#x02212;20 &#x000b0;C. Thiol-glycans
were dissolved in water at 30 mM concentration. A 66 &#x003bc;M protein&#x02013;phenylselenyl
conjugate in 10 mM CHES, 70 mM MES, and 2 mM CaCl<sub>2</sub> (pH
9.5) was supplemented with 3 mM thiol-glycan and the mixture was then
incubated for 20 min at 21 &#x000b0;C. Yield could be increased if additional
thiol-carbohydrate (final concentration 6 mM) was added after 20 min
and incubation at 21 &#x000b0;C was extended for another 20 min. The
IL-4&#x02013;carbohydrate conjugate was purified by RP-HPLC as described
above.</p></div><div id="sec4.4" class="sec"><h3 id="sec4.4title">Direct Coupling of Thiol-Carbohydrates to IL-4 Cysteine Variants
during Refolding</h3><p class="p p-first-last">The IL-4 protein (<em>E. coli</em>-derived IL-4 inclusion bodies or from expression in HEK293 cells;
for expression in HEK293 cells see the <a href="https://pubs.acs.org/doi/suppl/10.1021/acsomega.3c00726/suppl_file/ao3c00726_si_001.pdf" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">Supporting Information</a>) was denatured using 5.3 M GuHCl, 100 mM Tris&#x02013;HCl
(pH 8.0), 1 mM DTT at a protein concentration of about 1&#x02013;1.5
mg/mL (bacteria-derived insoluble protein) or 1 mg/mL (HEK293 cell-derived
protein). After stirring for 2 h at 21 &#x000b0;C the mixture was centrifuged
(35,000<em>g</em>, 4 &#x000b0;C, 30 min) and added to 25 volumes
of refolding buffer (1 M arginine, 50 mM Tris&#x02013;HCl, pH 8.0,
5 mM EDTA, 1 mM thiol-glycan). The refolding reaction was incubated
at 4 &#x000b0;C for 72 h. Thereafter the refolding mixture of <em>E. coli</em>-derived IL-4 proteins was dialyzed twice
for 12 h at 4 &#x000b0;C against 10 volumes of 25 mM ammonium acetate
pH 5.0. Refolded <em>E. coli</em>-derived IL-4
glycoconjugates were purified by cation exchange chromatography (HiTrap
CM Sepharose FF, GE Healthcare) using a gradient 0&#x02013;1.5 M NaCl
in 25 mM ammonium acetate (pH 5.0). Thereafter RP-HPLC was performed
using a C4 column (Jupiter C4, 10 &#x003bc;m, 250 mm &#x000d7; 10 mm, Phenomenex,
Germany) and a gradient of 0.1% TFA in H<sub>2</sub>O to 80% acetonitrile
in three column volumes. The refolding mixture for HEK293 cell-derived
IL-4 glycoconjugates was instead dialyzed twice for 12 h at 4 &#x000b0;C
against 10 volumes of 50 mM sodium phosphate and 300 mM NaCl (pH 8.3).
His-tagged HEK293 cell-derived IL-4 glycoconjugates were then isolated
using immobilized metal ion affinity chromatography (IMAC) employing
a 5 mL HisTrap Excel column (GE Healthcare) and a gradient of 10&#x02013;500
mM imidazole in 50 mM sodium phosphate (pH 8.3) and 300 mM NaCl. Protein-containing
fractions were pooled and dialyzed against 1 mM HCl.</p></div><div id="sec4.5" class="sec"><h3 id="sec4.5title">Cellular Assays for IL-4 Bioactivity</h3><p class="p p-first">TF-1 cells (ATCC
CRL2003) were maintained in RPMI-1640 (Gibco), 10% heat-inactivated
fetal calf serum (FCS, Biochrome), 100 &#x003bc;g/mL streptomycin, 100
U/mL penicillin, and 8 ng/mL human GM-CSF at 37 &#x000b0;C and 5% CO<sub>2</sub> in a humidified atmosphere. The day prior to the assay, cells
were diluted 1:1 with the fresh medium. Cell densities were adjusted
to (3&#x02013;4) &#x000d7; 10<sup>5</sup> cells/mL in the assay medium
(RPMI-1640 without phenol red and without GM-CSF supplementation)
and the cells were incubated for 4 h at 37 &#x000b0;C. To determine biological
activities (EC50), serial dilutions of IL-4 proteins were performed
in the assay medium in 96-well flat-bottom microtiter plates. Per
well, 100 &#x003bc;L assay medium containing the respective IL-4 protein
was added and plates were warmed to 37 &#x000b0;C. Then, 100 &#x003bc;L
of cell suspension was added per well and plates were incubated for
72 h. The metabolic rate was quantified by adding 10 &#x003bc;L of resazurin
solution (0.15 mg/mL in PBS) per well. In the presence of NADH or
NADPH, resazurin is converted to resorufin, which is quantified by
absorbance spectroscopy at 571 nm. After incubation for 4 h at 37
&#x000b0;C, absorbance was measured at 571 nm (background at 749 nm).
For quantification, signal intensities were normalized to the control,
which was 50 pM IL-4 WT. For competition experiments to determine
the half-maximal inhibitory concentration (IC50), a serial dilution
of the IL-4 antagonist protein was prepared in the assay medium containing
100 pM wild-type IL-4.</p><p class="p p-last">HEK-Blue IL-4/IL-13 cells (Invivogen)
were maintained in DMEM glutamax (Gibco), 10% heat-inactivated FBS,
100 &#x003bc;g/mL streptomycin, 100 U/mL penicillin, 100 &#x003bc;g/mL
zeocin, 10 &#x003bc;g/mL blasticidin at 37 &#x000b0;C, and 5% CO<sub>2</sub> in a humidified atmosphere. To determine biological activities of
IL-4 proteins serial dilutions were performed in the assay medium
(growth medium without phenol red) in 96-well flat-bottom microtiter
plates. Per well, 100 &#x003bc;L of the assay medium containing the
IL-4 protein was added and plates were warmed to 37 &#x000b0;C. HEK-Blue
cells were adjusted to 1 &#x000d7; 10<sup>5</sup> cells/mL in the assay
medium and 100 &#x003bc;L of the cell suspension was added to each well.
After 20&#x02013;24 h of incubation at 37 &#x000b0;C, the supernatant
was collected and a p-nitrophenyl phosphate assay was performed allowing
quantification of SEAP activity measuring absorbance at 405/630 nm.
For competition experiments to determine the half-maximal inhibitory
concentration (IC50) a serial dilution of the IL-4 antagonist protein
was prepared in the assay medium containing 100 pM wild-type IL-4.</p></div><div id="sec4.6" class="sec sec-last"><h3 id="sec4.6title">Proteolytic Stability Assay</h3><p class="p p-first-last">Proteins were dissolved
in 50 mM Tris&#x02013;HCl, 1 mM CaCl<sub>2</sub>, pH 7.6, and adjusted
to a concentration of 30&#x02013;32 &#x003bc;M. Five hundred microliters
of protein solution were mixed with 10 &#x003bc;g of trypsin (sequencing
grade trypsin, Promega, catalog number V5111) dissolved at 40 &#x003bc;M
in resuspension buffer (Promega), and the proteolysis setup was incubated
at 37 &#x000b0;C. At different time points, samples were taken, mixed
with 1:20 (v/v) protease inhibitor cocktail set III (Calbiochem),
and frozen at &#x02212;20 &#x000b0;C. For each protein sample, 5 &#x003bc;g
were subjected to SDS-PAGE analysis. After Coomassie staining gels
were analyzed using ImageLab software (Bio-Rad) using the volume tool.
Band intensities were normalized to protein bands of the molecular
weight standard. Values were analyzed statistically using the two-tailed <em>t</em>-test for independent samples (the threshold for the declaration
of statistical significance: <em>P</em> value &#x0003c; 0.05).</p></div></div><div id="ack-a.s.d" class="tsec sec"><h2 class="head no_bottom_margin" id="ack-a.s.dtitle">Acknowledgments</h2><div class="sec"><p>The work presented was supported by the
grant VIP 03V0557
(Bundesministerium f&#x000fc;r Forschung und Technik).</p></div></div><div id="dl1" class="tsec sec"><h2 class="head no_bottom_margin" id="dl1title">Glossary</h2><div class="bk-sec"><div><h4>Abbreviations</h4><table class="default-table glossary"><tbody><tr><td>IL</td><td>Interleukin</td></tr><tr><td>Th</td><td>T-helper cell</td></tr><tr><td>Ig</td><td>immunoglobulin</td></tr><tr><td>JAK</td><td>Janus kinase</td></tr><tr><td>STAT</td><td>Signal Transducers
and Activators
of Transcription</td></tr><tr><td>VCAM 1</td><td>Vascular Cell Adhesion Molecule 1</td></tr><tr><td>PEG</td><td>poly(ethylene glycol)</td></tr><tr><td>GSH</td><td>glutathione reduced</td></tr><tr><td>GSSG</td><td>glutathione oxidized</td></tr><tr><td>SMCC</td><td>succinimidyl-4-(<em>N</em>-maleimidomethyl)cyclohexane-1-carboxylate</td></tr><tr><td>NHS</td><td><em>N</em>-hydroxysuccinimide
ester</td></tr><tr><td>RT</td><td>room temperature</td></tr><tr><td>SPR</td><td>surface plasmon
resonance</td></tr><tr><td>HPLC</td><td>high-pressure
liquid chromatography</td></tr><tr><td>CHES</td><td><em>N</em>-cyclohexyl-2-aminoethanesulfonic acid</td></tr><tr><td>MES</td><td>2-(<em>N</em>-morpholino)ethanesulfonic acid</td></tr><tr><td>GuHCl</td><td>guanidine hydrochloride</td></tr><tr><td>DTT</td><td>dithiothreitol</td></tr><tr><td>EDTA</td><td>ethylenediaminetetraacetic acid</td></tr><tr><td>GM-CSF</td><td>granulocyte
macrophage colony-stimulating factor</td></tr><tr><td>EC<sub>50</sub></td><td>half-maximal effective concentration</td></tr><tr><td>IC<sub>50</sub></td><td>half-maximal
inhibitory concentration</td></tr><tr><td>SEAP</td><td>secreted alkaline phosphatase</td></tr></tbody></table></div></div></div><div id="notes-1" class="tsec sec"><h2 class="head no_bottom_margin" id="notes-1title">Supporting Information Available</h2><p>The Supporting Information
is available free of charge at <a href="https://pubs.acs.org/doi/10.1021/acsomega.3c00726?goto=supporting-info" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">https://pubs.acs.org/doi/10.1021/acsomega.3c00726</a>.</p><ul class="simple" style="list-style-type:none" id="silist"><li><div>Chemicals, protocols for removal of the non-conjugated
IL-4 protein with iodoacetyl-activated agarose, recombinant expression
of IL-4 in HEK293 cells, mass spectrometry analysis, surface plasmon
resonance (SPR) analysis, and periodic-acid&#x02013;Schiff staining
of glycosylated proteins. Data for RP-HPLC purification of SMCC glycoconjugate,
mass spectrometry, SPR data, enzymatic hydrolysis of N-linked oligosaccharides
in glycoengineered IL-4 variants, SDS-PAGE analysis, and trypsin proteolysis
experiments (<a href="https://pubs.acs.org/doi/suppl/10.1021/acsomega.3c00726/suppl_file/ao3c00726_si_001.pdf" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">PDF</a>)</div></li></ul><p></p></div><div id="NOTES-d14e1103-autogenerated" class="tsec sec"><h2 class="head no_bottom_margin" id="NOTES-d14e1103-autogeneratedtitle">Notes</h2><p>The authors declare no
competing financial interest.</p></div><div id="sec-a.s.b" class="tsec bk-sec"><a id="supplementary-material-sec"></a><h2 class="head no_bottom_margin" id="sec-a.s.btitle">Supplementary Material</h2><!--/article/back/sec/--><div class="sec suppmat" id="sifile1"><div class="sup-box half_rhythm" id="media-a.s.b.b.a"><a href="/pmc/articles/PMC10357448/bin/ao3c00726_si_001.pdf" data-ga-action="click_feat_suppl">ao3c00726_si_001.pdf</a><sup>(11M, pdf)</sup></div></div></div><div id="ref-list-a.s.f" class="tsec sec"><h2 class="head no_bottom_margin" id="ref-list-a.s.ftitle">References</h2><div class="ref-list-sec sec" id="reference-list"><ul class="back-ref-list" style="list-style-type:decimal;"><li id="ref1"><span class="mixed-citation" id="cit1">Hsieh C. S.; Heimberger A. B.; Gold J. S.; O&#x02019;Garra A.; Murphy K. M.
<span class="ref-title">Differential regulation of T helper phenotype development
by interleukins 4 and 10 in an alpha beta T-cell-receptor transgenic
system</span>. <span class="ref-journal">Proc. Natl. Acad. Sci. U.S.A.</span>
1992, <span class="ref-vol">89</span>, 6065&#x02013;6069. 10.1073/pnas.89.13.6065. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC49438/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/1385868" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1073%2Fpnas.89.13.6065" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proc.+Natl.+Acad.+Sci.+U.S.A.&amp;title=Differential+regulation+of+T+helper+phenotype+development&#10;by+interleukins+4+and+10+in+an+alpha+beta+T-cell-receptor+transgenic&#10;system&amp;author=C.+S.+Hsieh&amp;author=A.+B.+Heimberger&amp;author=J.+S.+Gold&amp;author=A.+O&#x02019;Garra&amp;author=K.+M.+Murphy&amp;volume=89&amp;publication_year=1992&amp;pages=6065-6069&amp;pmid=1385868&amp;doi=10.1073/pnas.89.13.6065&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref2"><span class="mixed-citation" id="cit2">Le
Gros G.; Ben-Sasson S. Z.; Seder R.; Finkelman F. D.; Paul W. E.
<span class="ref-title">Generation of interleukin 4 (IL-4)-producing cells
in vivo and in vitro: IL-2 and IL-4 are required for in vitro generation
of IL-4-producing cells</span>. <span class="ref-journal">J. Exp. Med.</span>
1990, <span class="ref-vol">172</span>, 921&#x02013;929. 10.1084/jem.172.3.921. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2188542/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/2117636" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1084%2Fjem.172.3.921" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J.+Exp.+Med.&amp;title=Generation+of+interleukin+4+(IL-4)-producing+cells&#10;in+vivo+and+in+vitro:+IL-2+and+IL-4+are+required+for+in+vitro+generation&#10;of+IL-4-producing+cells&amp;author=G.+Le&#10;Gros&amp;author=S.+Z.+Ben-Sasson&amp;author=R.+Seder&amp;author=F.+D.+Finkelman&amp;author=W.+E.+Paul&amp;volume=172&amp;publication_year=1990&amp;pages=921-929&amp;pmid=2117636&amp;doi=10.1084/jem.172.3.921&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref3"><span class="mixed-citation" id="cit3">Maggi E.; Parronchi P.; Manetti R.; Simonelli C.; Piccinni M. P.; Rugiu F. S.; De Carli M.; Ricci M.; Romagnani S.
<span class="ref-title">Reciprocal regulatory effects of IFN-gamma and IL-4
on the in vitro development of human Th1 and Th2 clones</span>. <span class="ref-journal">J. Immunol.</span>
1992, <span class="ref-vol">148</span>, 2142&#x02013;2147. 10.4049/jimmunol.148.7.2142. [<a href="https://pubmed.ncbi.nlm.nih.gov/1532000" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.4049%2Fjimmunol.148.7.2142" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J.+Immunol.&amp;title=Reciprocal+regulatory+effects+of+IFN-gamma+and+IL-4&#10;on+the+in+vitro+development+of+human+Th1+and+Th2+clones&amp;author=E.+Maggi&amp;author=P.+Parronchi&amp;author=R.+Manetti&amp;author=C.+Simonelli&amp;author=M.+P.+Piccinni&amp;volume=148&amp;publication_year=1992&amp;pages=2142-2147&amp;pmid=1532000&amp;doi=10.4049/jimmunol.148.7.2142&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref4"><span class="mixed-citation" id="cit4">Sornasse T.; Larenas P. V.; Davis K. A.; deVries J. E.; Yssel H.
<span class="ref-title">Differentiation
and stability of T helper 1 and 2 cells derived from naive human neonatal
CD4(+) T cells analyzed at the single-cell level</span>. <span class="ref-journal">J. Exp. Med.</span>
1996, <span class="ref-vol">184</span>, 473&#x02013;483. 10.1084/jem.184.2.473. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2192741/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/8760801" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1084%2Fjem.184.2.473" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J.+Exp.+Med.&amp;title=Differentiation&#10;and+stability+of+T+helper+1+and+2+cells+derived+from+naive+human+neonatal&#10;CD4(+)+T+cells+analyzed+at+the+single-cell+level&amp;author=T.+Sornasse&amp;author=P.+V.+Larenas&amp;author=K.+A.+Davis&amp;author=J.+E.+deVries&amp;author=H.+Yssel&amp;volume=184&amp;publication_year=1996&amp;pages=473-483&amp;pmid=8760801&amp;doi=10.1084/jem.184.2.473&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref5"><span class="mixed-citation" id="cit5">Abbas A. K.; Murphy K. M.; Sher A.
<span class="ref-title">Functional
diversity of helper T
lymphocytes</span>. <span class="ref-journal">Nature</span>
1996, <span class="ref-vol">383</span>, 787&#x02013;793. 10.1038/383787a0. [<a href="https://pubmed.ncbi.nlm.nih.gov/8893001" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2F383787a0" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Functional&#10;diversity+of+helper+T&#10;lymphocytes&amp;author=A.+K.+Abbas&amp;author=K.+M.+Murphy&amp;author=A.+Sher&amp;volume=383&amp;publication_year=1996&amp;pages=787-793&amp;pmid=8893001&amp;doi=10.1038/383787a0&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref6"><span class="mixed-citation" id="cit6">Nakamura T.; Lee R. K.; Nam S. Y.; Podack E. R.; Bottomly K.; Flavell R. A.
<span class="ref-title">Roles of IL-4 and IFN-gamma in stabilizing the T helper
cell type 1 and 2 phenotype</span>. <span class="ref-journal">J. Immunol.</span>
1997, <span class="ref-vol">158</span>, 2648&#x02013;2653. 10.4049/jimmunol.158.6.2648. [<a href="https://pubmed.ncbi.nlm.nih.gov/9058797" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.4049%2Fjimmunol.158.6.2648" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J.+Immunol.&amp;title=Roles+of+IL-4+and+IFN-gamma+in+stabilizing+the+T+helper&#10;cell+type+1+and+2+phenotype&amp;author=T.+Nakamura&amp;author=R.+K.+Lee&amp;author=S.+Y.+Nam&amp;author=E.+R.+Podack&amp;author=K.+Bottomly&amp;volume=158&amp;publication_year=1997&amp;pages=2648-2653&amp;pmid=9058797&amp;doi=10.4049/jimmunol.158.6.2648&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref7"><span class="mixed-citation" id="cit7">Parronchi P.; De Carli M.; Manetti R.; Simonelli C.; Sampognaro S.; Piccinni M. P.; Macchia D.; Maggi E.; Del Prete G.; Romagnani S.
<span class="ref-title">IL-4 and IFN
(alpha and gamma) exert
opposite regulatory effects on the development of cytolytic potential
by Th1 or Th2 human T cell clones</span>. <span class="ref-journal">J. Immunol.</span>
1992, <span class="ref-vol">149</span>, 2977&#x02013;2983. 10.4049/jimmunol.149.9.2977. [<a href="https://pubmed.ncbi.nlm.nih.gov/1401925" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.4049%2Fjimmunol.149.9.2977" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J.+Immunol.&amp;title=IL-4+and+IFN&#10;(alpha+and+gamma)+exert&#10;opposite+regulatory+effects+on+the+development+of+cytolytic+potential&#10;by+Th1+or+Th2+human+T+cell+clones&amp;author=P.+Parronchi&amp;author=M.+De+Carli&amp;author=R.+Manetti&amp;author=C.+Simonelli&amp;author=S.+Sampognaro&amp;volume=149&amp;publication_year=1992&amp;pages=2977-2983&amp;pmid=1401925&amp;doi=10.4049/jimmunol.149.9.2977&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref8"><span class="mixed-citation" id="cit8">Schleimer R. P.; Sterbinsky S. A.; Kaiser J.; Bickel C. A.; Klunk D. A.; Tomioka K.; Newman W.; Luscinskas F. W.; Gimbrone M. A.; McIntyre B. W.
<span class="ref-title">IL-4 induces
adherence of human eosinophils
and basophils but not neutrophils to endothelium. Association with
expression of VCAM-1</span>. <span class="ref-journal">J. Immunol.</span>
1992, <span class="ref-vol">148</span>, 1086&#x02013;1092. 10.4049/jimmunol.148.4.1086. [<a href="https://pubmed.ncbi.nlm.nih.gov/1371130" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.4049%2Fjimmunol.148.4.1086" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J.+Immunol.&amp;title=IL-4+induces&#10;adherence+of+human+eosinophils&#10;and+basophils+but+not+neutrophils+to+endothelium.+Association+with&#10;expression+of+VCAM-1&amp;author=R.+P.+Schleimer&amp;author=S.+A.+Sterbinsky&amp;author=J.+Kaiser&amp;author=C.+A.+Bickel&amp;author=D.+A.+Klunk&amp;volume=148&amp;publication_year=1992&amp;pages=1086-1092&amp;pmid=1371130&amp;doi=10.4049/jimmunol.148.4.1086&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref9"><span class="mixed-citation" id="cit9">Bochner B. S.; Klunk D. A.; Sterbinsky S. A.; Coffman R. L.; Schleimer R. P.
<span class="ref-title">IL-13 selectively
induces vascular cell adhesion molecule-1 expression in human endothelial
cells</span>. <span class="ref-journal">J. Immunol.</span>
1995, <span class="ref-vol">154</span>, 799&#x02013;803. 10.4049/jimmunol.154.2.799. [<a href="https://pubmed.ncbi.nlm.nih.gov/7529288" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.4049%2Fjimmunol.154.2.799" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J.+Immunol.&amp;title=IL-13+selectively&#10;induces+vascular+cell+adhesion+molecule-1+expression+in+human+endothelial&#10;cells&amp;author=B.+S.+Bochner&amp;author=D.+A.+Klunk&amp;author=S.+A.+Sterbinsky&amp;author=R.+L.+Coffman&amp;author=R.+P.+Schleimer&amp;volume=154&amp;publication_year=1995&amp;pages=799-803&amp;pmid=7529288&amp;doi=10.4049/jimmunol.154.2.799&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref10"><span class="mixed-citation" id="cit10">Lebman D. A.; Coffman R. L.
<span class="ref-title">Interleukin 4 causes isotype switching
to IgE in T
cell-stimulated clonal B cell cultures</span>. <span class="ref-journal">J. Exp.
Med.</span>
1988, <span class="ref-vol">168</span>, 853&#x02013;862. 10.1084/jem.168.3.853. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2189023/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/3049907" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1084%2Fjem.168.3.853" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J.+Exp.&#10;Med.&amp;title=Interleukin+4+causes+isotype+switching&#10;to+IgE+in+T&#10;cell-stimulated+clonal+B+cell+cultures&amp;author=D.+A.+Lebman&amp;author=R.+L.+Coffman&amp;volume=168&amp;publication_year=1988&amp;pages=853-862&amp;pmid=3049907&amp;doi=10.1084/jem.168.3.853&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref11"><span class="mixed-citation" id="cit11">Punnonen J.; Aversa G.; Cocks B. G.; McKenzie A. N.; Menon S.; Zurawski G.; de Waal
Malefyt R.; de Vries J. E.
<span class="ref-title">Interleukin 13 induces
interleukin 4-independent IgG4 and IgE synthesis and CD23 expression
by human B cells</span>. <span class="ref-journal">Proc. Natl. Acad. Sci. U.S.A.</span>
1993, <span class="ref-vol">90</span>, 3730&#x02013;3734. 10.1073/pnas.90.8.3730. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC46375/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/8097323" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1073%2Fpnas.90.8.3730" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proc.+Natl.+Acad.+Sci.+U.S.A.&amp;title=Interleukin+13+induces&#10;interleukin+4-independent+IgG4+and+IgE+synthesis+and+CD23+expression&#10;by+human+B+cells&amp;author=J.+Punnonen&amp;author=G.+Aversa&amp;author=B.+G.+Cocks&amp;author=A.+N.+McKenzie&amp;author=S.+Menon&amp;volume=90&amp;publication_year=1993&amp;pages=3730-3734&amp;pmid=8097323&amp;doi=10.1073/pnas.90.8.3730&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref12"><span class="mixed-citation" id="cit12">Defrance T.; Aubry J. P.; Rousset F.; Vanbervliet B.; Bonnefoy J. Y.; Arai N.; Takebe Y.; Yokota T.; Lee F.; Arai K.; et al. <span class="ref-title">Human recombinant interleukin 4 induces Fc
epsilon receptors (CD23) on normal human B lymphocytes</span>. <span class="ref-journal">J. Exp. Med.</span>
1987, <span class="ref-vol">165</span>, 1459&#x02013;1467. 10.1084/jem.165.6.1459. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2188364/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/2953844" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1084%2Fjem.165.6.1459" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J.+Exp.+Med.&amp;title=Human+recombinant+interleukin+4+induces+Fc&#10;epsilon+receptors+(CD23)+on+normal+human+B+lymphocytes&amp;author=T.+Defrance&amp;author=J.+P.+Aubry&amp;author=F.+Rousset&amp;author=B.+Vanbervliet&amp;author=J.+Y.+Bonnefoy&amp;volume=165&amp;publication_year=1987&amp;pages=1459-1467&amp;pmid=2953844&amp;doi=10.1084/jem.165.6.1459&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref13"><span class="mixed-citation" id="cit13">Defrance T.; Carayon P.; Billian G.; Guillemot J. C.; Minty A.; Caput D.; Ferrara P.
<span class="ref-title">Interleukin 13 is a
B cell stimulating factor</span>. <span class="ref-journal">J. Exp. Med.</span>
1994, <span class="ref-vol">179</span>, 135&#x02013;143. 10.1084/jem.179.1.135. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2191343/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/7903680" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1084%2Fjem.179.1.135" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J.+Exp.+Med.&amp;title=Interleukin+13+is+a&#10;B+cell+stimulating+factor&amp;author=T.+Defrance&amp;author=P.+Carayon&amp;author=G.+Billian&amp;author=J.+C.+Guillemot&amp;author=A.+Minty&amp;volume=179&amp;publication_year=1994&amp;pages=135-143&amp;pmid=7903680&amp;doi=10.1084/jem.179.1.135&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref14"><span class="mixed-citation" id="cit14">Toru H.; Ra C.; Nonoyama S.; Suzuki K.; Yata J.; Nakahata T.
<span class="ref-title">Induction
of the high-affinity IgE receptor (Fc epsilon RI) on human mast cells
by IL-4</span>. <span class="ref-journal">Int. Immunol.</span>
1996, <span class="ref-vol">8</span>, 1367&#x02013;1373. 10.1093/intimm/8.9.1367. [<a href="https://pubmed.ncbi.nlm.nih.gov/8921414" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1093%2Fintimm%2F8.9.1367" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Int.+Immunol.&amp;title=Induction&#10;of+the+high-affinity+IgE+receptor+(Fc+epsilon+RI)+on+human+mast+cells&#10;by+IL-4&amp;author=H.+Toru&amp;author=C.+Ra&amp;author=S.+Nonoyama&amp;author=K.+Suzuki&amp;author=J.+Yata&amp;volume=8&amp;publication_year=1996&amp;pages=1367-1373&amp;pmid=8921414&amp;doi=10.1093/intimm/8.9.1367&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref15"><span class="mixed-citation" id="cit15">Xia H. Z.; Du Z.; Craig S.; Klisch G.; Noben-Trauth N.; Kochan J. P.; Huff T. H.; Irani A. M.; Schwartz L. B.
<span class="ref-title">Effect
of recombinant human IL-4 on tryptase, chymase, and Fc epsilon receptor
type I expression in recombinant human stem cell factor-dependent
fetal liver-derived human mast cells</span>. <span class="ref-journal">J. Immunol.</span>
1997, <span class="ref-vol">159</span>, 2911&#x02013;2921. 10.4049/jimmunol.159.6.2911. [<a href="https://pubmed.ncbi.nlm.nih.gov/9300715" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.4049%2Fjimmunol.159.6.2911" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J.+Immunol.&amp;title=Effect&#10;of+recombinant+human+IL-4+on+tryptase,+chymase,+and+Fc+epsilon+receptor&#10;type+I+expression+in+recombinant+human+stem+cell+factor-dependent&#10;fetal+liver-derived+human+mast+cells&amp;author=H.+Z.+Xia&amp;author=Z.+Du&amp;author=S.+Craig&amp;author=G.+Klisch&amp;author=N.+Noben-Trauth&amp;volume=159&amp;publication_year=1997&amp;pages=2911-2921&amp;pmid=9300715&amp;doi=10.4049/jimmunol.159.6.2911&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref16"><span class="mixed-citation" id="cit16">May R. D.; Fung M.
<span class="ref-title">Strategies targeting
the IL-4/IL-13 axes in disease</span>. <span class="ref-journal">Cytokine</span>
2015, <span class="ref-vol">75</span>, 89&#x02013;116. 10.1016/j.cyto.2015.05.018. [<a href="https://pubmed.ncbi.nlm.nih.gov/26255210" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.cyto.2015.05.018" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cytokine&amp;title=Strategies+targeting&#10;the+IL-4/IL-13+axes+in+disease&amp;author=R.+D.+May&amp;author=M.+Fung&amp;volume=75&amp;publication_year=2015&amp;pages=89-116&amp;pmid=26255210&amp;doi=10.1016/j.cyto.2015.05.018&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref17"><span class="mixed-citation" id="cit17">Stone K. D.; Prussin C.; Metcalfe D. D.
<span class="ref-title">IgE, mast
cells, basophils, and eosinophils</span>. <span class="ref-journal">J. Allergy
Clin. Immunol.</span>
2010, <span class="ref-vol">125</span>, S73&#x02013;80. 10.1016/j.jaci.2009.11.017. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2847274/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20176269" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.jaci.2009.11.017" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J.+Allergy&#10;Clin.+Immunol.&amp;title=IgE,+mast&#10;cells,+basophils,+and+eosinophils&amp;author=K.+D.+Stone&amp;author=C.+Prussin&amp;author=D.+D.+Metcalfe&amp;volume=125&amp;publication_year=2010&amp;pages=S73-80&amp;pmid=20176269&amp;doi=10.1016/j.jaci.2009.11.017&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref18"><span class="mixed-citation" id="cit18">Lauffer F.; Ring J.
<span class="ref-title">Target-oriented therapy:
Emerging drugs for atopic dermatitis</span>. <span class="ref-journal">Expert
Opin. Emerging Drugs</span>
2016, <span class="ref-vol">21</span>, 81&#x02013;89. 10.1517/14728214.2016.1146681. [<a href="https://pubmed.ncbi.nlm.nih.gov/26808004" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1517%2F14728214.2016.1146681" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Expert&#10;Opin.+Emerging+Drugs&amp;title=Target-oriented+therapy:&#10;Emerging+drugs+for+atopic+dermatitis&amp;author=F.+Lauffer&amp;author=J.+Ring&amp;volume=21&amp;publication_year=2016&amp;pages=81-89&amp;doi=10.1517/14728214.2016.1146681&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref19"><span class="mixed-citation" id="cit19">Mueller T. D.; Zhang J. L.; Sebald W.; Duschl A.
<span class="ref-title">Structure, binding,
and antagonists in the IL-4/IL-13 receptor system</span>. <span class="ref-journal">Biochim. Biophys. Acta, Mol. Cell Res.</span>
2002, <span class="ref-vol">1592</span>, 237&#x02013;250. 10.1016/S0167-4889(02)00318-X. [<a href="https://pubmed.ncbi.nlm.nih.gov/12421669" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2FS0167-4889(02)00318-X" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biochim.+Biophys.+Acta,+Mol.+Cell+Res.&amp;title=Structure,+binding,&#10;and+antagonists+in+the+IL-4/IL-13+receptor+system&amp;author=T.+D.+Mueller&amp;author=J.+L.+Zhang&amp;author=W.+Sebald&amp;author=A.+Duschl&amp;volume=1592&amp;publication_year=2002&amp;pages=237-250&amp;doi=10.1016/S0167-4889(02)00318-X&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref20"><span class="mixed-citation" id="cit20">Obiri N. I.; Debinski W.; Leonard W. J.; Puri R. K.
<span class="ref-title">Receptor
for interleukin
13. Interaction with interleukin 4 by a mechanism that does not involve
the common gamma chain shared by receptors for interleukins 2, 4,
7, 9, and 15</span>. <span class="ref-journal">J. Biol. Chem.</span>
1995, <span class="ref-vol">270</span>, 8797&#x02013;8804. 10.1074/jbc.270.15.8797. [<a href="https://pubmed.ncbi.nlm.nih.gov/7721786" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1074%2Fjbc.270.15.8797" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J.+Biol.+Chem.&amp;title=Receptor&#10;for+interleukin&#10;13.+Interaction+with+interleukin+4+by+a+mechanism+that+does+not+involve&#10;the+common+gamma+chain+shared+by+receptors+for+interleukins+2,+4,&#10;7,+9,+and+15&amp;author=N.+I.+Obiri&amp;author=W.+Debinski&amp;author=W.+J.+Leonard&amp;author=R.+K.+Puri&amp;volume=270&amp;publication_year=1995&amp;pages=8797-8804&amp;pmid=7721786&amp;doi=10.1074/jbc.270.15.8797&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref21"><span class="mixed-citation" id="cit21">Lin J. X.; Leonard W. J.
<span class="ref-title">The Common Cytokine Receptor gamma Chain Family of
Cytokines</span>. <span class="ref-journal">Cold Spring Harbor Perspect. Biol.</span>
2018, <span class="ref-vol">10</span>, a028449 10.1101/cshperspect.a028449. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6120701/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29038115" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1101%2Fcshperspect.a028449" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cold+Spring+Harbor+Perspect.+Biol.&amp;title=The+Common+Cytokine+Receptor+gamma+Chain+Family+of&#10;Cytokines&amp;author=J.+X.+Lin&amp;author=W.+J.+Leonard&amp;volume=10&amp;publication_year=2018&amp;pages=a028449&amp;doi=10.1101/cshperspect.a028449&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref22"><span class="mixed-citation" id="cit22">Ul-Haq Z.; Naz S.; Mesaik M. A.
<span class="ref-title">Interleukin-4
receptor signaling and its binding mechanism:
A therapeutic insight from inhibitors tool box</span>. <span class="ref-journal">Cytokine Growth Factor Rev.</span>
2016, <span class="ref-vol">32</span>, 3&#x02013;15. 10.1016/j.cytogfr.2016.04.002. [<a href="https://pubmed.ncbi.nlm.nih.gov/27165851" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.cytogfr.2016.04.002" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cytokine+Growth+Factor+Rev.&amp;title=Interleukin-4&#10;receptor+signaling+and+its+binding+mechanism:&#10;A+therapeutic+insight+from+inhibitors+tool+box&amp;author=Z.+Ul-Haq&amp;author=S.+Naz&amp;author=M.+A.+Mesaik&amp;volume=32&amp;publication_year=2016&amp;pages=3-15&amp;pmid=27165851&amp;doi=10.1016/j.cytogfr.2016.04.002&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref23"><span class="mixed-citation" id="cit23">Gandhi N. A.; Pirozzi G.; Graham N. M. H.
<span class="ref-title">Commonality
of the IL-4/IL-13 pathway
in atopic diseases</span>. <span class="ref-journal">Expert Rev. Clin. Immunol.</span>
2017, <span class="ref-vol">13</span>, 425&#x02013;437. 10.1080/1744666X.2017.1298443. [<a href="https://pubmed.ncbi.nlm.nih.gov/28277826" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1080%2F1744666X.2017.1298443" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Expert+Rev.+Clin.+Immunol.&amp;title=Commonality&#10;of+the+IL-4/IL-13+pathway&#10;in+atopic+diseases&amp;author=N.+A.+Gandhi&amp;author=G.+Pirozzi&amp;author=N.+M.+H.+Graham&amp;volume=13&amp;publication_year=2017&amp;pages=425-437&amp;pmid=28277826&amp;doi=10.1080/1744666X.2017.1298443&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref24"><span class="mixed-citation" id="cit24">Barranco P.; Phillips-Angles E.; Dominguez-Ortega J.; Quirce S.
<span class="ref-title">Dupilumab in the management
of moderate-to-severe asthma: the data so far</span>. <span class="ref-journal">Ther. Clin. Risk Manage.</span>
2017, <span class="ref-vol">13</span>, 1139&#x02013;1149. 10.2147/TCRM.S125964. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5589101/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28979129" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.2147%2FTCRM.S125964" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Ther.+Clin.+Risk+Manage.&amp;title=Dupilumab+in+the+management&#10;of+moderate-to-severe+asthma:+the+data+so+far&amp;author=P.+Barranco&amp;author=E.+Phillips-Angles&amp;author=J.+Dominguez-Ortega&amp;author=S.+Quirce&amp;volume=13&amp;publication_year=2017&amp;pages=1139-1149&amp;doi=10.2147/TCRM.S125964&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref25"><span class="mixed-citation" id="cit25">Tofte S. J.; Papp K.; Sadick N.; Bohnert K.; Simpson E.; Thaci D.; Bieber T.; Blauvelt A.; Sofen H.; Gooderham M.; Chen Z.; Gadkari A.; Eckert L.; Graham N. M. H.; Pirozzi G.; Ardeleanu M.
<span class="ref-title">Efficacy and
safety of dupilumab for the treatment of moderate-to-severe atopic
dermatitis in adults: A pooled analysis of two phase 2 clinical trials</span>. <span class="ref-journal">J. Am. Assoc. Nurse Pract.</span>
2018, <span class="ref-vol">30</span>, 529&#x02013;541. 10.1097/JXX.0000000000000088. [<a href="https://pubmed.ncbi.nlm.nih.gov/30211823" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1097%2FJXX.0000000000000088" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J.+Am.+Assoc.+Nurse+Pract.&amp;title=Efficacy+and&#10;safety+of+dupilumab+for+the+treatment+of+moderate-to-severe+atopic&#10;dermatitis+in+adults:+A+pooled+analysis+of+two+phase+2+clinical+trials&amp;author=S.+J.+Tofte&amp;author=K.+Papp&amp;author=N.+Sadick&amp;author=K.+Bohnert&amp;author=E.+Simpson&amp;volume=30&amp;publication_year=2018&amp;pages=529-541&amp;pmid=30211823&amp;doi=10.1097/JXX.0000000000000088&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref26"><span class="mixed-citation" id="cit26">Kruse N.; Tony H. P.; Sebald W.
<span class="ref-title">Conversion of Human
Interleukin-4
into a High-Affinity Antagonist by a Single Amino-Acid Replacement</span>. <span class="ref-journal">EMBO J.</span>
1992, <span class="ref-vol">11</span>, 3237&#x02013;3244. 10.1002/j.1460-2075.1992.tb05401.x. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC556857/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/1387082" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1002%2Fj.1460-2075.1992.tb05401.x" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=EMBO+J.&amp;title=Conversion+of+Human&#10;Interleukin-4&#10;into+a+High-Affinity+Antagonist+by+a+Single+Amino-Acid+Replacement&amp;author=N.+Kruse&amp;author=H.+P.+Tony&amp;author=W.+Sebald&amp;volume=11&amp;publication_year=1992&amp;pages=3237-3244&amp;pmid=1387082&amp;doi=10.1002/j.1460-2075.1992.tb05401.x&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref27"><span class="mixed-citation" id="cit27">Kruse N.; Shen B. J.; Arnold S.; Tony H. P.; Muller T.; Sebald W.
<span class="ref-title">2 Distinct Functional
Sites of Human Interleukin-4
Are Identified by Variants Impaired in Either Receptor-Binding or
Receptor Activation</span>. <span class="ref-journal">EMBO J.</span>
1993, <span class="ref-vol">12</span>, 5121&#x02013;5129. 10.1002/j.1460-2075.1993.tb06207.x. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC413774/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/8262056" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1002%2Fj.1460-2075.1993.tb06207.x" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=EMBO+J.&amp;title=2+Distinct+Functional&#10;Sites+of+Human+Interleukin-4&#10;Are+Identified+by+Variants+Impaired+in+Either+Receptor-Binding+or&#10;Receptor+Activation&amp;author=N.+Kruse&amp;author=B.+J.+Shen&amp;author=S.+Arnold&amp;author=H.+P.+Tony&amp;author=T.+Muller&amp;volume=12&amp;publication_year=1993&amp;pages=5121-5129&amp;pmid=8262056&amp;doi=10.1002/j.1460-2075.1993.tb06207.x&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref28"><span class="mixed-citation" id="cit28">Tony H. P.; Shen B. J.; Reusch P.; Sebald W.
<span class="ref-title">Design of human interleukin-4
antagonists inhibiting interleukin-4-dependent and interleukin-13-dependent
responses in T-cells and B-cells with high efficiency</span>. <span class="ref-journal">Eur. J. Biochem.</span>
1994, <span class="ref-vol">225</span>, 659&#x02013;665. 10.1111/j.1432-1033.1994.00659.x. [<a href="https://pubmed.ncbi.nlm.nih.gov/7957181" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1111%2Fj.1432-1033.1994.00659.x" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Eur.+J.+Biochem.&amp;title=Design+of+human+interleukin-4&#10;antagonists+inhibiting+interleukin-4-dependent+and+interleukin-13-dependent&#10;responses+in+T-cells+and+B-cells+with+high+efficiency&amp;author=H.+P.+Tony&amp;author=B.+J.+Shen&amp;author=P.+Reusch&amp;author=W.+Sebald&amp;volume=225&amp;publication_year=1994&amp;pages=659-665&amp;pmid=7957181&amp;doi=10.1111/j.1432-1033.1994.00659.x&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref29"><span class="mixed-citation" id="cit29">Wenzel S.; Wilbraham D.; Fuller R.; Getz E. B.; Longphre M.
<span class="ref-title">Effect of
an interleukin-4 variant on late phase asthmatic response to allergen
challenge in asthmatic patients: results of two phase 2a studies</span>. <span class="ref-journal">Lancet</span>
2007, <span class="ref-vol">370</span>, 1422&#x02013;1431. 10.1016/S0140-6736(07)61600-6. [<a href="https://pubmed.ncbi.nlm.nih.gov/17950857" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2FS0140-6736(07)61600-6" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Effect+of&#10;an+interleukin-4+variant+on+late+phase+asthmatic+response+to+allergen&#10;challenge+in+asthmatic+patients:+results+of+two+phase+2a+studies&amp;author=S.+Wenzel&amp;author=D.+Wilbraham&amp;author=R.+Fuller&amp;author=E.+B.+Getz&amp;author=M.+Longphre&amp;volume=370&amp;publication_year=2007&amp;pages=1422-1431&amp;pmid=17950857&amp;doi=10.1016/S0140-6736(07)61600-6&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref30"><span class="mixed-citation" id="cit30">Longphre M. V.; Fuller R. W.. <span class="ref-title">Aerovant (recombinant
human interleukin-4 variant)</span>. In <span class="ref-journal">New Drugs
and Targets for Asthma and COPD</span>; Hansel T. T.; Barnes P. J., Eds.; KARGER: Basel, 2010; Vol. <span class="ref-vol">39</span>, pp 123&#x02013;126. <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?title=New+Drugs&#10;and+Targets+for+Asthma+and+COPD&amp;publication_year=2010&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref31"><span class="mixed-citation" id="cit31">Tomkinson A.<span class="ref-title">Use
of modified
il-4 mutien receptor antagonists to treat dermatitis</span>. WO2011106779, PCT/US2011/026521, February 28, 2011.</span></li><li id="ref32"><span class="mixed-citation" id="cit32">M&#x000fc;ller T.; Sebald W.; Oschkinat H.
<span class="ref-title">Antagonist design through forced
electrostatic mismatch</span>. <span class="ref-journal">Nat. Struct. Mol. Biol.</span>
1994, <span class="ref-vol">1</span>, 674&#x02013;676. 10.1038/nsb1094-674. [<a href="https://pubmed.ncbi.nlm.nih.gov/7634067" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fnsb1094-674" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat.+Struct.+Mol.+Biol.&amp;title=Antagonist+design+through+forced&#10;electrostatic+mismatch&amp;author=T.+M&#x000fc;ller&amp;author=W.+Sebald&amp;author=H.+Oschkinat&amp;volume=1&amp;publication_year=1994&amp;pages=674-676&amp;doi=10.1038/nsb1094-674&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref33"><span class="mixed-citation" id="cit33">Duppatla V.; Gjorgjevikj M.; Schmitz W.; Kottmair M.; Mueller T. D.; Sebald W.
<span class="ref-title">Enzymatic deglutathionylation to
generate interleukin-4
cysteine muteins with free thiol</span>. <span class="ref-journal">Bioconjugate
Chem.</span>
2012, <span class="ref-vol">23</span>, 1396&#x02013;1405. 10.1021/bc2004389. [<a href="https://pubmed.ncbi.nlm.nih.gov/22681442" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1021%2Fbc2004389" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Bioconjugate&#10;Chem.&amp;title=Enzymatic+deglutathionylation+to&#10;generate+interleukin-4&#10;cysteine+muteins+with+free+thiol&amp;author=V.+Duppatla&amp;author=M.+Gjorgjevikj&amp;author=W.+Schmitz&amp;author=M.+Kottmair&amp;author=T.+D.+Mueller&amp;volume=23&amp;publication_year=2012&amp;pages=1396-1405&amp;doi=10.1021/bc2004389&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref34"><span class="mixed-citation" id="cit34">Duppatla V.; Gjorgjevikj M.; Schmitz W.; Hermanns H. M.; Schafer C. M.; Kottmair M.; Muller T.; Sebald W.
<span class="ref-title">IL-4 analogues with
site-specific chemical modification at position 121 inhibit IL-4 and
IL-13 biological activities</span>. <span class="ref-journal">Bioconjugate Chem.</span>
2014, <span class="ref-vol">25</span>, 52&#x02013;62. 10.1021/bc400307k. [<a href="https://pubmed.ncbi.nlm.nih.gov/24341642" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1021%2Fbc400307k" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Bioconjugate+Chem.&amp;title=IL-4+analogues+with&#10;site-specific+chemical+modification+at+position+121+inhibit+IL-4+and&#10;IL-13+biological+activities&amp;author=V.+Duppatla&amp;author=M.+Gjorgjevikj&amp;author=W.+Schmitz&amp;author=H.+M.+Hermanns&amp;author=C.+M.+Schafer&amp;volume=25&amp;publication_year=2014&amp;pages=52-62&amp;doi=10.1021/bc400307k&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref35"><span class="mixed-citation" id="cit35">Zhang F.; Liu M. R.; Wan H. T.
<span class="ref-title">Discussion about Several Potential
Drawbacks of PEGylated Therapeutic Proteins</span>. <span class="ref-journal">Biol. Pharm. Bull.</span>
2014, <span class="ref-vol">37</span>, 335&#x02013;339. 10.1248/bpb.b13-00661. [<a href="https://pubmed.ncbi.nlm.nih.gov/24334536" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1248%2Fbpb.b13-00661" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biol.+Pharm.+Bull.&amp;title=Discussion+about+Several+Potential&#10;Drawbacks+of+PEGylated+Therapeutic+Proteins&amp;author=F.+Zhang&amp;author=M.+R.+Liu&amp;author=H.+T.+Wan&amp;volume=37&amp;publication_year=2014&amp;pages=335-339&amp;pmid=24334536&amp;doi=10.1248/bpb.b13-00661&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref36"><span class="mixed-citation" id="cit36">Elliott S.; Lorenzini T.; Asher S.; Aoki K.; Brankow D.; Buck L.; Busse L.; Chang D.; Fuller J.; Grant J.; Hernday N.; Hokum M.; Hu S.; Knudten A.; Levin N.; Komorowski R.; Martin F.; Navarro R.; Osslund T.; Rogers G.; Rogers N.; Trail G.; Egrie J.
<span class="ref-title">Enhancement of therapeutic
protein in vivo activities through glycoengineering</span>. <span class="ref-journal">Nat. Biotechnol.</span>
2003, <span class="ref-vol">21</span>, 414&#x02013;421. 10.1038/nbt799. [<a href="https://pubmed.ncbi.nlm.nih.gov/12612588" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fnbt799" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat.+Biotechnol.&amp;title=Enhancement+of+therapeutic&#10;protein+in+vivo+activities+through+glycoengineering&amp;author=S.+Elliott&amp;author=T.+Lorenzini&amp;author=S.+Asher&amp;author=K.+Aoki&amp;author=D.+Brankow&amp;volume=21&amp;publication_year=2003&amp;pages=414-421&amp;pmid=12612588&amp;doi=10.1038/nbt799&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref37"><span class="mixed-citation" id="cit37">Sola R. J.; Griebenow K.
<span class="ref-title">Glycosylation
of therapeutic proteins: an effective
strategy to optimize efficacy</span>. <span class="ref-journal">BioDrugs</span>
2010, <span class="ref-vol">24</span>, 9&#x02013;21. 10.2165/11530550-000000000-00000. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2805475/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20055529" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.2165%2F11530550-000000000-00000" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=BioDrugs&amp;title=Glycosylation&#10;of+therapeutic+proteins:+an+effective&#10;strategy+to+optimize+efficacy&amp;author=R.+J.+Sola&amp;author=K.+Griebenow&amp;volume=24&amp;publication_year=2010&amp;pages=9-21&amp;pmid=20055529&amp;doi=10.2165/11530550-000000000-00000&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref38"><span class="mixed-citation" id="cit38">Carr C.; Aykent S.; Kimack N. M.; Levine A. D.
<span class="ref-title">Disulfide assignments
in recombinant mouse and human interleukin 4</span>. <span class="ref-journal">Biochemistry</span>
1991, <span class="ref-vol">30</span>, 1515&#x02013;1523. 10.1021/bi00220a011. [<a href="https://pubmed.ncbi.nlm.nih.gov/1993171" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1021%2Fbi00220a011" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biochemistry&amp;title=Disulfide+assignments&#10;in+recombinant+mouse+and+human+interleukin+4&amp;author=C.+Carr&amp;author=S.+Aykent&amp;author=N.+M.+Kimack&amp;author=A.+D.+Levine&amp;volume=30&amp;publication_year=1991&amp;pages=1515-1523&amp;pmid=1993171&amp;doi=10.1021/bi00220a011&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref39"><span class="mixed-citation" id="cit39">Spicer C. D.; Davis B. G.
<span class="ref-title">Selective chemical
protein modification</span>. <span class="ref-journal">Nat. Commun.</span>
2014, <span class="ref-vol">5</span>, 4740 10.1038/ncomms5740. [<a href="https://pubmed.ncbi.nlm.nih.gov/25190082" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fncomms5740" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat.+Commun.&amp;title=Selective+chemical&#10;protein+modification&amp;author=C.+D.+Spicer&amp;author=B.+G.+Davis&amp;volume=5&amp;publication_year=2014&amp;pages=4740&amp;pmid=25190082&amp;doi=10.1038/ncomms5740&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref40"><span class="mixed-citation" id="cit40">Kraich M.; Klein M.; Patino E.; Harrer H.; Nickel J.; Sebald W.; Mueller T. D.
<span class="ref-title">A modular interface of IL-4 allows
for scalable affinity without affecting specificity for the IL-4 receptor</span>. <span class="ref-journal">BMC Biol.</span>
2006, <span class="ref-vol">4</span>, 13 10.1186/1741-7007-4-13. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1479839/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16640778" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1186%2F1741-7007-4-13" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=BMC+Biol.&amp;title=A+modular+interface+of+IL-4+allows&#10;for+scalable+affinity+without+affecting+specificity+for+the+IL-4+receptor&amp;author=M.+Kraich&amp;author=M.+Klein&amp;author=E.+Patino&amp;author=H.+Harrer&amp;author=J.+Nickel&amp;volume=4&amp;publication_year=2006&amp;pages=13&amp;pmid=16640778&amp;doi=10.1186/1741-7007-4-13&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref41"><span class="mixed-citation" id="cit41">Hermanson G. T.<span class="ref-journal">Bioconjugate Techniques</span>, 3rd
ed.; Academic Press: London, 2013; p 1146. <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?title=Bioconjugate+Techniques&amp;publication_year=2013&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref42"><span class="mixed-citation" id="cit42">Yoshitake S.; Yamada Y.; Ishikawa E.; Masseyeff R.
<span class="ref-title">Conjugation
of glucose oxidase from Aspergillus niger and rabbit antibodies using
N-hydroxysuccinimide ester of N-(4-carboxycyclohexylmethyl)-maleimide</span>. <span class="ref-journal">Eur. J. Biochem.</span>
1979, <span class="ref-vol">101</span>, 395&#x02013;399. 10.1111/j.1432-1033.1979.tb19731.x. [<a href="https://pubmed.ncbi.nlm.nih.gov/574817" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1111%2Fj.1432-1033.1979.tb19731.x" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Eur.+J.+Biochem.&amp;title=Conjugation&#10;of+glucose+oxidase+from+Aspergillus+niger+and+rabbit+antibodies+using&#10;N-hydroxysuccinimide+ester+of+N-(4-carboxycyclohexylmethyl)-maleimide&amp;author=S.+Yoshitake&amp;author=Y.+Yamada&amp;author=E.+Ishikawa&amp;author=R.+Masseyeff&amp;volume=101&amp;publication_year=1979&amp;pages=395-399&amp;pmid=574817&amp;doi=10.1111/j.1432-1033.1979.tb19731.x&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref43"><span class="mixed-citation" id="cit43">Gamblin D. P.; Garnier P.; van Kasteren S.; Oldham N. J.; Fairbanks A. J.; Davis B. G.
<span class="ref-title">Glyco-SeS: selenenylsulfide-mediated
protein glycoconjugation--a
new strategy in post-translational modification</span>. <span class="ref-journal">Angew. Chem., Int. Ed.</span>
2004, <span class="ref-vol">43</span>, 828&#x02013;833. 10.1002/anie.200352975. [<a href="https://pubmed.ncbi.nlm.nih.gov/14767951" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1002%2Fanie.200352975" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Angew.+Chem.,+Int.+Ed.&amp;title=Glyco-SeS:+selenenylsulfide-mediated&#10;protein+glycoconjugation--a&#10;new+strategy+in+post-translational+modification&amp;author=D.+P.+Gamblin&amp;author=P.+Garnier&amp;author=S.+van+Kasteren&amp;author=N.+J.+Oldham&amp;author=A.+J.+Fairbanks&amp;volume=43&amp;publication_year=2004&amp;pages=828-833&amp;doi=10.1002/anie.200352975&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref44"><span class="mixed-citation" id="cit44">Bernardes G. J. L.; Gamblin D. P.; Davis B. G.
<span class="ref-title">The direct
formation of glycosyl
thiols from reducing sugars allows one-pot protein glycoconjugation</span>. <span class="ref-journal">Angew. Chem., Int. Ed.</span>
2006, <span class="ref-vol">45</span>, 4007&#x02013;4011. 10.1002/anie.200600685. [<a href="https://pubmed.ncbi.nlm.nih.gov/16673441" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1002%2Fanie.200600685" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Angew.+Chem.,+Int.+Ed.&amp;title=The+direct&#10;formation+of+glycosyl&#10;thiols+from+reducing+sugars+allows+one-pot+protein+glycoconjugation&amp;author=G.+J.+L.+Bernardes&amp;author=D.+P.+Gamblin&amp;author=B.+G.+Davis&amp;volume=45&amp;publication_year=2006&amp;pages=4007-4011&amp;doi=10.1002/anie.200600685&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref45"><span class="mixed-citation" id="cit45">van
Kasteren S. I.; Kramer H. B.; Gamblin D. P.; Davis B. G.
<span class="ref-title">Site-selective
glycosylation of proteins: creating synthetic glycoproteins</span>. <span class="ref-journal">Nat. Protoc.</span>
2007, <span class="ref-vol">2</span>, 3185&#x02013;3194. 10.1038/nprot.2007.430. [<a href="https://pubmed.ncbi.nlm.nih.gov/18079718" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fnprot.2007.430" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat.+Protoc.&amp;title=Site-selective&#10;glycosylation+of+proteins:+creating+synthetic+glycoproteins&amp;author=S.+I.+van&#10;Kasteren&amp;author=H.+B.+Kramer&amp;author=D.+P.+Gamblin&amp;author=B.+G.+Davis&amp;volume=2&amp;publication_year=2007&amp;pages=3185-3194&amp;pmid=18079718&amp;doi=10.1038/nprot.2007.430&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref46"><span class="mixed-citation" id="cit46">Shen B. J.; Hage T.; Sebald W.
<span class="ref-title">Global and
local determinants for
the kinetics of interleukin-4/interleukin-4 receptor alpha chain interaction.
A biosensor study employing recombinant interleukin-4-binding protein</span>. <span class="ref-journal">Eur. J. Biochem.</span>
1996, <span class="ref-vol">240</span>, 252&#x02013;261. 10.1111/j.1432-1033.1996.0252h.x. [<a href="https://pubmed.ncbi.nlm.nih.gov/8797861" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1111%2Fj.1432-1033.1996.0252h.x" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Eur.+J.+Biochem.&amp;title=Global+and&#10;local+determinants+for&#10;the+kinetics+of+interleukin-4/interleukin-4+receptor+alpha+chain+interaction.&#10;A+biosensor+study+employing+recombinant+interleukin-4-binding+protein&amp;author=B.+J.+Shen&amp;author=T.+Hage&amp;author=W.+Sebald&amp;volume=240&amp;publication_year=1996&amp;pages=252-261&amp;pmid=8797861&amp;doi=10.1111/j.1432-1033.1996.0252h.x&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref47"><span class="mixed-citation" id="cit47">LaPorte S. L.; Juo Z. S.; Vaclavikova J.; Colf L. A.; Qi X.; Heller N. M.; Keegan A. D.; Garcia K. C.
<span class="ref-title">Molecular and structural
basis of cytokine receptor pleiotropy in the interleukin-4/13 system</span>. <span class="ref-journal">Cell</span>
2008, <span class="ref-vol">132</span>, 259&#x02013;272. 10.1016/j.cell.2007.12.030. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2265076/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18243101" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.cell.2007.12.030" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=Molecular+and+structural&#10;basis+of+cytokine+receptor+pleiotropy+in+the+interleukin-4/13+system&amp;author=S.+L.+LaPorte&amp;author=Z.+S.+Juo&amp;author=J.+Vaclavikova&amp;author=L.+A.+Colf&amp;author=X.+Qi&amp;volume=132&amp;publication_year=2008&amp;pages=259-272&amp;pmid=18243101&amp;doi=10.1016/j.cell.2007.12.030&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref48"><span class="mixed-citation" id="cit48">Lefort S.; Vita N.; Reeb R.; Caput D.; Ferrara P.
<span class="ref-title">Il-13 and
Il-4 Share Signal-Transduction Elements as Well as Receptor Components
in Tf-1 Cells</span>. <span class="ref-journal">FEBS Lett.</span>
1995, <span class="ref-vol">366</span>, 122&#x02013;126. 10.1016/0014-5793(95)00512-8. [<a href="https://pubmed.ncbi.nlm.nih.gov/7789528" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2F0014-5793(95)00512-8" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=FEBS+Lett.&amp;title=Il-13+and&#10;Il-4+Share+Signal-Transduction+Elements+as+Well+as+Receptor+Components&#10;in+Tf-1+Cells&amp;author=S.+Lefort&amp;author=N.+Vita&amp;author=R.+Reeb&amp;author=D.+Caput&amp;author=P.+Ferrara&amp;volume=366&amp;publication_year=1995&amp;pages=122-126&amp;pmid=7789528&amp;doi=10.1016/0014-5793(95)00512-8&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref49"><span class="mixed-citation" id="cit49">Shanafelt A. B.; Forte C. P.; Kasper J. J.; Sanchez-Pescador L.; Wetzel M.; Gundel R.; Greve J. M.
<span class="ref-title">An immune cell-selective
interleukin 4 agonist</span>. <span class="ref-journal">Proc. Natl. Acad. Sci.
U.S.A.</span>
1998, <span class="ref-vol">95</span>, 9454&#x02013;9458. 10.1073/pnas.95.16.9454. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC21359/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/9689101" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1073%2Fpnas.95.16.9454" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proc.+Natl.+Acad.+Sci.&#10;U.S.A.&amp;title=An+immune+cell-selective&#10;interleukin+4+agonist&amp;author=A.+B.+Shanafelt&amp;author=C.+P.+Forte&amp;author=J.+J.+Kasper&amp;author=L.+Sanchez-Pescador&amp;author=M.+Wetzel&amp;volume=95&amp;publication_year=1998&amp;pages=9454-9458&amp;pmid=9689101&amp;doi=10.1073/pnas.95.16.9454&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref50"><span class="mixed-citation" id="cit50">Cheng Y.; Prusoff W. H.
<span class="ref-title">Relationship between
the inhibition constant (K1) and
the concentration of inhibitor which causes 50 per cent inhibition
(I50) of an enzymatic reaction</span>. <span class="ref-journal">Biochem. Pharmacol.</span>
1973, <span class="ref-vol">22</span>, 3099&#x02013;3108. 10.1016/0006-2952(73)90196-2. [<a href="https://pubmed.ncbi.nlm.nih.gov/4202581" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2F0006-2952(73)90196-2" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biochem.+Pharmacol.&amp;title=Relationship+between&#10;the+inhibition+constant+(K1)+and&#10;the+concentration+of+inhibitor+which+causes+50+per+cent+inhibition&#10;(I50)+of+an+enzymatic+reaction&amp;author=Y.+Cheng&amp;author=W.+H.+Prusoff&amp;volume=22&amp;publication_year=1973&amp;pages=3099-3108&amp;pmid=4202581&amp;doi=10.1016/0006-2952(73)90196-2&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref51"><span class="mixed-citation" id="cit51">Carter C. R. D.; Whitmore K. M.; Thorpe R.
<span class="ref-title">The significance
of carbohydrates
on G-CSF: differential sensitivity of G-CSFs to human neutrophil elastase
degradation</span>. <span class="ref-journal">J. Leukocyte Biol.</span>
2004, <span class="ref-vol">75</span>, 515&#x02013;522. 10.1189/jlb.0803378. [<a href="https://pubmed.ncbi.nlm.nih.gov/14657210" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1189%2Fjlb.0803378" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J.+Leukocyte+Biol.&amp;title=The+significance&#10;of+carbohydrates&#10;on+G-CSF:+differential+sensitivity+of+G-CSFs+to+human+neutrophil+elastase&#10;degradation&amp;author=C.+R.+D.+Carter&amp;author=K.+M.+Whitmore&amp;author=R.+Thorpe&amp;volume=75&amp;publication_year=2004&amp;pages=515-522&amp;pmid=14657210&amp;doi=10.1189/jlb.0803378&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref52"><span class="mixed-citation" id="cit52">Ueda T.; Tomita K.; Notsu Y.; Ito T.; Fumoto M.; Takakura T.; Nagatome H.; Takimoto A.; Mihara S.; Togame H.; Kawamoto K.; Iwasaki T.; Asakura K.; Oshima T.; Hanasaki K.; Nishimura S.; Kondo H.
<span class="ref-title">Chemoenzymatic synthesis of glycosylated glucagon-like peptide 1:
effect of glycosylation on proteolytic resistance and in vivo blood
glucose-lowering activity</span>. <span class="ref-journal">J. Am. Chem. Soc.</span>
2009, <span class="ref-vol">131</span>, 6237&#x02013;6245. 10.1021/ja900261g. [<a href="https://pubmed.ncbi.nlm.nih.gov/19361194" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1021%2Fja900261g" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J.+Am.+Chem.+Soc.&amp;title=Chemoenzymatic+synthesis+of+glycosylated+glucagon-like+peptide+1:&#10;effect+of+glycosylation+on+proteolytic+resistance+and+in+vivo+blood&#10;glucose-lowering+activity&amp;author=T.+Ueda&amp;author=K.+Tomita&amp;author=Y.+Notsu&amp;author=T.+Ito&amp;author=M.+Fumoto&amp;volume=131&amp;publication_year=2009&amp;pages=6237-6245&amp;pmid=19361194&amp;doi=10.1021/ja900261g&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li><li id="ref53"><span class="mixed-citation" id="cit53">Ghaderi D.; Zhang M.; Hurtado-Ziola N.; Varki A.
<span class="ref-title">Production platforms
for biotherapeutic glycoproteins. Occurrence, impact, and challenges
of non-human sialylation</span>. <span class="ref-journal">Biotechnol. Genet.
Eng. Rev.</span>
2012, <span class="ref-vol">28</span>, 147&#x02013;175. 10.5661/bger-28-147. [<a href="https://pubmed.ncbi.nlm.nih.gov/22616486" ref="reftype=pubmed&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.5661%2Fbger-28-147" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biotechnol.+Genet.&#10;Eng.+Rev.&amp;title=Production+platforms&#10;for+biotherapeutic+glycoproteins.+Occurrence,+impact,+and+challenges&#10;of+non-human+sialylation&amp;author=D.+Ghaderi&amp;author=M.+Zhang&amp;author=N.+Hurtado-Ziola&amp;author=A.+Varki&amp;volume=28&amp;publication_year=2012&amp;pages=147-175&amp;pmid=22616486&amp;doi=10.5661/bger-28-147&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10357448&amp;issue-id=441082&amp;journal-id=3686&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></li></ul></div></div></div><!--post-content--><div class="courtesy-note whole_rhythm small"><hr /><div class="half_rhythm">Articles from <span class="acknowledgment-journal-title">ACS Omega</span> are provided here courtesy of <strong>American Chemical Society</strong></div><hr /></div><div id="body-link-poppers"><span></span></div></div>
            
        </section>
    </article>
    <aside class="usa-width-one-fourth usa-layout-docs-sidenav pmc-sidebar">
         
  

<div class="scroller">

    
        <section>
                <h6>Other Formats</h6>
                <ul class="pmc-sidebar__formats">
                  <li class="pdf-link other_item"><a href="/pmc/articles/PMC10357448/pdf/ao3c00726.pdf" class="int-view">PDF (3.6M)</a></li>
                </ul>
        </section>
    
    <section>
        <h6>Actions</h6>
        <ul class="pmc-sidebar__actions">
            <li>
                <button role="button" class="citation-button citation-dialog-trigger ctxp"
                        aria-label="Open dialog with citation text in different styles" data-ga-category="save_share" data-ga-action="cite" data-ga-label="open"
                        data-all-citations-url="/pmc/resources/citations/10357448/"
                        data-citation-style="nlm"
                        data-download-format-link="/pmc/resources/citations/10357448/export/"
                >
                    <span class="button-label">Cite</span>
                </button>
            </li>
            <li>
                
                    

<link type="text/css" href="ncbi-overlay-block/src/overlay-block.css">
<div class="collections-button-container" data-article-id="10357448" data-article-db="pmc">
  <button class="collections-button collections-dialog-trigger"
          aria-label="Save article in MyNCBI collections."
          data-ga-category="collections_button"
          data-ga-action="click"
          data-ga-label="collections_button"
          data-collections-open-dialog-enabled="false"
          data-collections-open-dialog-url="https://www.ncbi.nlm.nih.gov/account?back_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC10357448%2F%23open-collections-dialog"
          data-in-collections="false">
      <span class="button-label">Collections</span>
  </button>
  <div class="overlay" role="dialog">
  <div id="collections-action-dialog"
       class="dialog collections-dialog"
       aria-hidden="true">
    <div class="title">Add to Collections</div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/pmc/list-existing-collections/"
      data-add-to-existing-collection-url="/pmc/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/pmc/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

  <input type="hidden" name="csrfmiddlewaretoken" value="d9A397gTuTqXwDRLcgTatroHPN2kvzWZKX0aeLVnpLI6E5ox4Tte33sAW5seDmEH">

  

  <div class="choice-group" role="radiogroup">
    <ul class="radio-group-items">
      <li>
        <input type="radio"
               id="collections-action-dialog-new-aside "
               class="collections-new"
               name="collections"
               value="new"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_new">
        <label for="collections-action-dialog-new-aside ">Create a new collection</label>
      </li>
      <li>
        <input type="radio"
               id="collections-action-dialog-existing-aside "
               class="collections-existing"
               name="collections"
               value="existing"
               checked="true"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_existing">
        <label for="collections-action-dialog-existing-aside ">Add to an existing collection</label>
      </li>
    </ul>
  </div>

  <div class="controls-wrapper">
    <div class="action-panel-control-wrap new-collections-controls">
      <label for="collections-action-dialog-add-to-new" class="action-panel-label required-field-asterisk">
        Name your collection:
      </label>
      <input
        type="text"
        name="add-to-new-collection"
        id="collections-action-dialog-add-to-new"
        class="collections-action-add-to-new"
        pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
        maxlength=""
        data-ga-category="collections_button"
        data-ga-action="create_collection"
        data-ga-label="non_favorties_collection">
      <div class="collections-new-name-too-long usa-input-error-message selection-validation-message">
        Name must be less than  characters
      </div>
    </div>
    <div class="action-panel-control-wrap existing-collections-controls">
      <label for="collections-action-dialog-add-to-existing" class="action-panel-label">
        Choose a collection:
      </label>
      <select id="collections-action-dialog-add-to-existing"
              class="action-panel-selector collections-action-add-to-existing"
              data-ga-category="collections_button"
              data-ga-action="select_collection"
              data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
      </select>
      <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
        Unable to load your collection due to an error<br>
        <a href="#">Please try again</a>
      </div>
    </div>
  </div>

  <div class="action-panel-actions">
    <button class="action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
      Add
    </button>
    <button class="action-panel-cancel"
            aria-label="Close 'Add to Collections' panel"
            ref="linksrc=close_collections_panel"
            aria-controls="collections-action-panel"
            aria-expanded="false"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="cancel">
      Cancel
    </button>
  </div>
</form>
    </div>
  </div>
</div>
</div>
                
            </li>

        </ul>
    </section>
    
        <section class="social-sharing">
            <h6>Share</h6>
            <ul class="pmc-sidebar__share">
                <li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC10357448%2F&amp;text=Design%20of%20Glycoengineered%0AIL-4%20Antagonists%0AEmploying%20Chemical%20and%20Biosynthetic%20Glycosylation" alt="Share on Twitter"><i class="fa fa-twitter fa-stack-1x">&#160;</i></a></li> 
<li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC10357448%2F" alt="Share on Facebook"><i class="fa fa-facebook fa-stack-1x">&#160;</i></a></li>
                <li>
                    <div class="share-permalink">
                        <button class="trigger"  alt="Show article permalink" aria-expanded="false" aria-haspopup="true">
                            <i class="fa-stack fa-lg" >
                                <i class="fa fa-link fa-stack-1x">&nbsp;</i>
                            </i>
                        </button>
                        <div class="dropdown dropdown-container" hidden>
                              <div class="title">
                                Permalink
                              </div>
                              <div class="content">
                                  <input type="text" class="permalink-text" value="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357448/" aria-label="Article permalink"><button class="permalink-copy-button usa-button-primary" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                                      <span class="button-title">Copy</span>
                                  </button>
                              </div>
                        </div>
                    </div>
                </li>
            </ul>
        </section>
    
    <section>
        <h6>RESOURCES</h6>
        <ul class="pmc-sidebar__resources">
        
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_similar_articles"
                            data-ga-label="/pmc/articles/PMC10357448/"
                            class="usa-accordion-button"
                            aria-controls="similar-articles-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_similar_articles"
                            data-action-close="close_similar_articles"
                    >
                        Similar articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/similar-article-links/37483220/"
                            

                         class="usa-accordion-content pmc-sidebar__resources--citations" id="similar-articles-accordion-aside" aria-hidden="true">
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_cited_by"
                            data-ga-label="/pmc/articles/PMC10357448/"
                            class="usa-accordion-button"
                            aria-controls="cited-by-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_cited_by"
                            data-action-close="close_cited_by"
                    >
                        Cited by other articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/cited-by-links/37483220/"
                            
                            class="usa-accordion-content pmc-sidebar__resources--citations"
                            id="cited-by-accordion-aside"
                            aria-hidden="true"
                    >
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/pmc/articles/PMC10357448/"
                            class="usa-accordion-button"
                            aria-controls="links-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                    >
                        Links to NCBI Databases
                    </button>
                    <div data-source-url="/pmc/resources/db-links/10357448/" class="usa-accordion-content" id="links-accordion-aside" aria-hidden="true"></div>
                </div>
            </li>

            
        
        </ul>
    </section>

 </div>

    </aside>
</main>

    <div class="overlay" role="dialog" aria-label="Citation Dialog">
  <div class="dialog citation-dialog">
    <button class="close-overlay" tabindex="1">[x]</button>
    <div class="title">Cite</div>
    <div class="citation-text-block">
  <div class="citation-text"></div>
  <div class="citation-actions">
    <button
      class="copy-button dialog-focus"
      data-ga-category="save_share"
      data-ga-action="cite"
      data-ga-label="copy"
      tabindex="2">
      Copy
    </button>

      <a href="#"
              class="export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
          <span class="title">Download .nbib</span>
          <span class="title-mobile">.nbib</span>
      </a>


    

<div class="citation-style-selector-wrapper">
  <label class="selector-label">Format:</label>
  <select aria-label="Format" class="citation-style-selector" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
  </div>
</div>
  </div>
</div>

     <!-- ========== BEGIN FOOTER ========== -->
 <footer>
      <section class="icon-section">
        <div id="icon-section-header" class="icon-section_header">Follow NCBI</div>
        <div class="grid-container container">
          <div class="icon-section_container">
            <a class="footer-icon" id="footer_twitter" href="https://twitter.com/ncbi" aria-label="Twitter"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <defs>
                  <style>
                    .cls-11 {
                      fill: #737373;
                    }
                  </style>
                </defs>
                <title>Twitter</title>
                <path class="cls-11"
                  d="M250.11,105.48c-7,3.14-13,3.25-19.27.14,8.12-4.86,8.49-8.27,11.43-17.46a78.8,78.8,0,0,1-25,9.55,39.35,39.35,0,0,0-67,35.85,111.6,111.6,0,0,1-81-41.08A39.37,39.37,0,0,0,81.47,145a39.08,39.08,0,0,1-17.8-4.92c0,.17,0,.33,0,.5a39.32,39.32,0,0,0,31.53,38.54,39.26,39.26,0,0,1-17.75.68,39.37,39.37,0,0,0,36.72,27.3A79.07,79.07,0,0,1,56,223.34,111.31,111.31,0,0,0,116.22,241c72.3,0,111.83-59.9,111.83-111.84,0-1.71,0-3.4-.1-5.09C235.62,118.54,244.84,113.37,250.11,105.48Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_facebook" href="https://www.facebook.com/ncbi.nlm" aria-label="Facebook"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <title>Facebook</title>
                <path class="cls-11"
                  d="M210.5,115.12H171.74V97.82c0-8.14,5.39-10,9.19-10h27.14V52l-39.32-.12c-35.66,0-42.42,26.68-42.42,43.77v19.48H99.09v36.32h27.24v109h45.41v-109h35Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_linkedin"
              href="https://www.linkedin.com/company/ncbinlm"
              aria-label="LinkedIn"><svg data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <title>LinkedIn</title>
                <path class="cls-11"
                  d="M101.64,243.37H57.79v-114h43.85Zm-22-131.54h-.26c-13.25,0-21.82-10.36-21.82-21.76,0-11.65,8.84-21.15,22.33-21.15S101.7,78.72,102,90.38C102,101.77,93.4,111.83,79.63,111.83Zm100.93,52.61A17.54,17.54,0,0,0,163,182v61.39H119.18s.51-105.23,0-114H163v13a54.33,54.33,0,0,1,34.54-12.66c26,0,44.39,18.8,44.39,55.29v58.35H198.1V182A17.54,17.54,0,0,0,180.56,164.44Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_github" href="https://github.com/ncbi" aria-label="GitHub"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <defs>
                  <style>
                    .cls-11,
                    .cls-12 {
                      fill: #737373;
                    }

                    .cls-11 {
                      fill-rule: evenodd;
                    }
                  </style>
                </defs>
                <title>GitHub</title>
                <path class="cls-11"
                  d="M151.36,47.28a105.76,105.76,0,0,0-33.43,206.1c5.28,1,7.22-2.3,7.22-5.09,0-2.52-.09-10.85-.14-19.69-29.42,6.4-35.63-12.48-35.63-12.48-4.81-12.22-11.74-15.47-11.74-15.47-9.59-6.56.73-6.43.73-6.43,10.61.75,16.21,10.9,16.21,10.9,9.43,16.17,24.73,11.49,30.77,8.79,1-6.83,3.69-11.5,6.71-14.14C108.57,197.1,83.88,188,83.88,147.51a40.92,40.92,0,0,1,10.9-28.39c-1.1-2.66-4.72-13.42,1-28,0,0,8.88-2.84,29.09,10.84a100.26,100.26,0,0,1,53,0C198,88.3,206.9,91.14,206.9,91.14c5.76,14.56,2.14,25.32,1,28a40.87,40.87,0,0,1,10.89,28.39c0,40.62-24.74,49.56-48.29,52.18,3.79,3.28,7.17,9.71,7.17,19.58,0,14.15-.12,25.54-.12,29,0,2.82,1.9,6.11,7.26,5.07A105.76,105.76,0,0,0,151.36,47.28Z">
                </path>
                <path class="cls-12"
                  d="M85.66,199.12c-.23.52-1.06.68-1.81.32s-1.2-1.06-.95-1.59,1.06-.69,1.82-.33,1.21,1.07.94,1.6Zm-1.3-1">
                </path>
                <path class="cls-12"
                  d="M90,203.89c-.51.47-1.49.25-2.16-.49a1.61,1.61,0,0,1-.31-2.19c.52-.47,1.47-.25,2.17.49s.82,1.72.3,2.19Zm-1-1.08">
                </path>
                <path class="cls-12"
                  d="M94.12,210c-.65.46-1.71,0-2.37-.91s-.64-2.07,0-2.52,1.7,0,2.36.89.65,2.08,0,2.54Zm0,0"></path>
                <path class="cls-12"
                  d="M99.83,215.87c-.58.64-1.82.47-2.72-.41s-1.18-2.06-.6-2.7,1.83-.46,2.74.41,1.2,2.07.58,2.7Zm0,0">
                </path>
                <path class="cls-12"
                  d="M107.71,219.29c-.26.82-1.45,1.2-2.64.85s-2-1.34-1.74-2.17,1.44-1.23,2.65-.85,2,1.32,1.73,2.17Zm0,0">
                </path>
                <path class="cls-12"
                  d="M116.36,219.92c0,.87-1,1.59-2.24,1.61s-2.29-.68-2.3-1.54,1-1.59,2.26-1.61,2.28.67,2.28,1.54Zm0,0">
                </path>
                <path class="cls-12"
                  d="M124.42,218.55c.15.85-.73,1.72-2,1.95s-2.37-.3-2.52-1.14.73-1.75,2-2,2.37.29,2.53,1.16Zm0,0"></path>
              </svg></a>
            <a class="footer-icon" id="footer_blog" href="https://ncbiinsights.ncbi.nlm.nih.gov/" aria-label="Blog">
              <svg id="Layer_1" data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 40"><defs><style>.cls-1{fill:#737373;}</style></defs><path class="cls-1" d="M14,30a4,4,0,1,1-4-4,4,4,0,0,1,4,4Zm11,3A19,19,0,0,0,7.05,15a1,1,0,0,0-1,1v3a1,1,0,0,0,.93,1A14,14,0,0,1,20,33.07,1,1,0,0,0,21,34h3a1,1,0,0,0,1-1Zm9,0A28,28,0,0,0,7,6,1,1,0,0,0,6,7v3a1,1,0,0,0,1,1A23,23,0,0,1,29,33a1,1,0,0,0,1,1h3A1,1,0,0,0,34,33Z"/></svg>
            </a>
          </div>
        </div>
      </section>

      <section class="container-fluid bg-primary">
        <div class="container pt-5">
          <div class="row mt-3">
            <div class="col-lg-3 col-12">
              <p><a class="text-white" href="https://www.nlm.nih.gov/socialmedia/index.html">Connect with NLM</a></p>
              <ul class="list-inline social_media">
                <li class="list-inline-item"><a href="https://twitter.com/NLM_NIH" aria-label="Twitter"
                    target="_blank" rel="noopener noreferrer"><svg version="1.1" xmlns="http://www.w3.org/2000/svg"
                      xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 249 249"
                      style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <style type="text/css">
                        .st20 {
                          fill: #FFFFFF;
                        }

                        .st30 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }
                      </style>
                      <title>SM-Twitter</title>
                      <g>
                        <g>
                          <g>
                            <path class="st20" d="M192.9,88.1c-5,2.2-9.2,2.3-13.6,0.1c5.7-3.4,6-5.8,8.1-12.3c-5.4,3.2-11.4,5.5-17.6,6.7
                                                c-10.5-11.2-28.1-11.7-39.2-1.2c-7.2,6.8-10.2,16.9-8,26.5c-22.3-1.1-43.1-11.7-57.2-29C58,91.6,61.8,107.9,74,116
                                                c-4.4-0.1-8.7-1.3-12.6-3.4c0,0.1,0,0.2,0,0.4c0,13.2,9.3,24.6,22.3,27.2c-4.1,1.1-8.4,1.3-12.5,0.5c3.6,11.3,14,19,25.9,19.3
                                                c-11.6,9.1-26.4,13.2-41.1,11.5c12.7,8.1,27.4,12.5,42.5,12.5c51,0,78.9-42.2,78.9-78.9c0-1.2,0-2.4-0.1-3.6
                                                C182.7,97.4,189.2,93.7,192.9,88.1z"></path>
                          </g>
                        </g>
                        <circle class="st30" cx="124.4" cy="128.8" r="108.2"></circle>
                      </g>
                    </svg></a></li>
                <li class="list-inline-item"><a href="https://www.facebook.com/nationallibraryofmedicine"
                    aria-label="Facebook" rel="noopener noreferrer" target="_blank">
                    <svg version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px"
                      y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <style type="text/css">
                        .st10 {
                          fill: #FFFFFF;
                        }

                        .st110 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }
                      </style>
                      <title>SM-Facebook</title>
                      <g>
                        <g>
                          <path class="st10" d="M159,99.1h-24V88.4c0-5,3.3-6.2,5.7-6.2h16.8V60l-24.4-0.1c-22.1,0-26.2,16.5-26.2,27.1v12.1H90v22.5h16.9
                                                      v67.5H135v-67.5h21.7L159,99.1z"></path>
                        </g>
                      </g>
                      <circle class="st110" cx="123.6" cy="123.2" r="108.2"></circle>
                    </svg>
                  </a></li>
                <li class="list-inline-item"><a href="https://www.youtube.com/user/NLMNIH" aria-label="Youtube"
                    target="_blank" rel="noopener noreferrer"><svg version="1.1" xmlns="http://www.w3.org/2000/svg"
                      xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 249 249"
                      style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <title>SM-Youtube</title>
                      <style type="text/css">
                        .st4 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }

                        .st5 {
                          fill: #FFFFFF;
                        }
                      </style>
                      <circle class="st4" cx="124.2" cy="123.4" r="108.2"></circle>
                      <g transform="translate(0,-952.36218)">
                        <path class="st5"
                          d="M88.4,1037.4c-10.4,0-18.7,8.3-18.7,18.7v40.1c0,10.4,8.3,18.7,18.7,18.7h72.1c10.4,0,18.7-8.3,18.7-18.7
                                            v-40.1c0-10.4-8.3-18.7-18.7-18.7H88.4z M115.2,1058.8l29.4,17.4l-29.4,17.4V1058.8z"></path>
                      </g>
                    </svg></a></li>
              </ul>
            </div>
            <div class="col-lg-3 col-12">
              <p class="address_footer text-white">National Library of Medicine<br>
                <a href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323"
                  class="text-white" target="_blank" rel="noopener noreferrer">8600 Rockville Pike<br>
                  Bethesda, MD 20894</a></p>
            </div>
            <div class="col-lg-3 col-12 centered-lg">
              <p><a href="https://www.nlm.nih.gov/web_policies.html" class="text-white">Web Policies</a><br>
                <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office"
                  class="text-white">FOIA</a><br>
                <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="text-white" id="vdp">HHS Vulnerability Disclosure</a></p>
            </div>
            <div class="col-lg-3 col-12 centered-lg">
              <p><a class="supportLink text-white" href="https://support.nlm.nih.gov/">Help</a><br>
                <a href="https://www.nlm.nih.gov/accessibility.html" class="text-white">Accessibility</a><br>
                <a href="https://www.nlm.nih.gov/careers/careers.html" class="text-white">Careers</a></p>
            </div>
          </div>
          <div class="row">
            <div class="col-lg-12 centered-lg">
              <nav class="bottom-links">
                <ul class="mt-3">
                  <li>
                    <a class="text-white" href="//www.nlm.nih.gov/">NLM</a>
                  </li>
                  <li>
                    <a class="text-white"
                  href="https://www.nih.gov/">NIH</a>
                  </li>
                  <li>
                    <a class="text-white" href="https://www.hhs.gov/">HHS</a>
                  </li>
                  <li>
                    <a
                  class="text-white" href="https://www.usa.gov/">USA.gov</a>
                  </li>
                </ul>
              </nav>
            </div>
          </div>
        </div>
      </section>
    </footer>
 <!-- ========== END FOOTER ========== -->
  <!-- javascript to inject NWDS meta tags. Note: value of nwds_version is updated by "npm version" command -->
 
  <script type="text/javascript">
    var nwds_version = "1.1.9-2";

    var meta_nwds_ver = document.createElement('meta');
    meta_nwds_ver.name = 'ncbi_nwds_ver';
    meta_nwds_ver.content = nwds_version;
    document.getElementsByTagName('head')[0].appendChild(meta_nwds_ver);

    var meta_nwds = document.createElement('meta');
    meta_nwds.name = 'ncbi_nwds';
    meta_nwds.content = 'yes';
    document.getElementsByTagName('head')[0].appendChild(meta_nwds);

	var alertsUrl = "/core/alerts/alerts.js";
	if (typeof ncbiBaseUrl !== 'undefined') {
		alertsUrl = ncbiBaseUrl + alertsUrl;
	}
  </script>



  
    <!-- JavaScript -->
    <script src="/pmc/static/CACHE/js/output.0f72d6a64937.js"></script>
  
  
    <script src="https://code.jquery.com/jquery-3.5.0.min.js"
          integrity="sha256-xNzN2a4ltkB44Mc/Jz3pT4iU1cmeR0FkXs4pru/JxaQ="
          crossorigin="anonymous">
    </script>
    <script>
        var fallbackJquery = "/pmc/static/base/js/jquery-3.5.0.min.js";
        window.jQuery || document.write("<script src=" + fallbackJquery + ">\x3C/script>")
    </script>
  

  <script src="/pmc/static/CACHE/js/output.a212a9fcf845.js"></script>
<script src="/pmc/static/CACHE/js/output.7999321d1aac.js"></script>
<script src="/pmc/static/CACHE/js/output.7ca436b2ea51.js"></script>
<script src="/pmc/static/CACHE/js/output.f8422046fbe0.js"></script>
<script src="/pmc/static/CACHE/js/output.ff40c7d85ff8.js"></script>
<script src="/pmc/static/CACHE/js/output.a6a84a0ad361.js"></script>

<script type="text/javascript" src="/pmc/static/bundles/base/base.038d36e4e31104b40a19.js" ></script>

    <script type="text/javascript">
        if(typeof jQuery !=='undefined') {
            jQuery.migrateMute = true;
        }
    </script>
    <script type="text/javascript" src="https://code.jquery.com/jquery-migrate-1.4.1.js"></script>
    <script type="text/javascript" src="/core/jig/1.15.2/js/jig.nojquery.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/crb.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/jactions.min.js?_=3.18">//</script><script type="text/javascript">window.name="mainwindow";</script>

    <script type="text/javascript">var exports = {};</script>
    <script src="/pmc/static/CACHE/js/output.340a3b9cce7f.js"></script>
<script src="/pmc/static/CACHE/js/output.228f96f3298e.js"></script>
    <script type="text/javascript" src="/pmc/static/bundles/article/article.b7dd20e527283dd68f45.js" ></script>
    <script type="text/javascript">
        window.ncbi.pmc.articlePage.init({ pageURL: '/pmc/articles/PMC10357448/', citeCookieName: 'pmc-cf'});
    </script>


  
  
  <script  type="text/javascript" src="https://www.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


  
      
  

</body>
</html>
